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ABSTRACT 
The rise of antibiotic-resistant bacteria poses a large problem for healthcare 
systems across the world. This problem is further exacerbated by the lack of 
development in new types of antibiotics. The CDC has identified antibiotic development 
as one of the key solutions in combating antibiotic resistance. Lantibiotics, a class of 
posttranslationally modified (PTM) peptide antibiotics, are promising candidates for 
antibiotic development. Lantibiotics are characterized by the presence of lanthionine 
rings and dehydrated residues. Mutacin 1140, produced by Streptococcus mutans 
JH1140, is a lantibiotic which has shown promising activity against a variety of Gram-
positive pathogens. Although lantibiotics, such as mutacin 1140 show promise, they are 
still hampered by the lack of development. Furthering the understanding of lantibiotic 
biosynthesis is crucial for promoting the development of lantibiotics.  
Lantibiotic biosynthesis requires a leader peptide for efficient posttranslational 
modification, which is then cleaved off to produce the full lantibiotic. A novel four 
amino acid EDLF motif was found to be important for biosynthesis in Mutacin 1140. 
Additionally, I have shown that a second cleavage occurs 8 amino acids upstream of the 
defined MutP cleavage site, and that this cleavage event is dependent upon position and 
not sequence. I sought to determine the importance of different PTM’s in the formation 
for the coordination of PTMs and transport of mutacin 1140. Deletion of the lanthionine 
rings show that lanthionine ring formation affects other PTM’s, and that it is important 
for transport out of the cytoplasm. 
iii 
The role of the unique S-[(Z)-2-aminovinyl]-D-cysteine (AviCys) residue found 
in mutacin 1140 is poorly understood. Removal of the C-terminal carboxyl group 
increases the antibiotic's affinity to its molecular target lipid II. A carboxyl variant of 
mutacin 1140 does not affect the other PTM’s and is important for activity. This variant 
is agreeable to the chemical addition of a wide variety of substrates, producing novel 
variants of mutacin 1140 with restored activity class of lantibiotics that can be screened 
for improvements in drug development. The advancements made in understanding the 
mutacin 1140 biosynthesis pathway will help in developing mutacin 1140 as a tool to 
help combat the problem of antibiotic resistance. 
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NOMENCLATURE 
AviCys S-[(Z)-2-aminovinyl]-D-cysteine 
DAP Diamino pimelate 
Dha 2,3-didehydroalanine 
Dhb 2,3-didehydrobutyrine 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
FPLC Fast protein liquid chromatography 
LD50 50% of lethal concentration 
HOAt 1-Hydroxy-7-azabenzotriazole 
HPLC High performance liquid chromatography 
MALDI-MS Matrix-assisted laser desorption/ionization - Mass spectrometry 
MDR Multi-drug resistant 
MIC Minimum inhibitory concentration 
MIC50 50% of minimum inhibitory concentration 
MRSA Methicillin-resistant Staphylococcus aureus 
NRPS Nonribosomal peptide synthetases 
PTM Postranslational modification 
SOPMA Self-optimized prediction method with alignment 
SPPS Solid-phase peptide synthesis 
VREF Vancomycin-resistant Enterococcus faecium 
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CHAPTER I: 
LITERATURE REVIEW: MULTIPRONGED APPROACH FOR 
ENGINEERING NOVEL PEPTIDE ANALOGS OF EXISTING LANTIBIOTICS
*
I.1. Introduction 
The emergence of multi drug-resistant (MDR) strains of bacteria poses a 
significant threat to public health and has cost the healthcare system billions of dollars 
annually (1-3). MDR bacteria are one of the leading causes of hospital acquired 
infections and have led to an increase in patient deaths worldwide (4, 5). This problem is 
further exacerbated by the lack of development of new antibiotics that can help combat 
MDR bacteria (6-8). Lantibiotics, a class of ribosomally-produced and 
posttranslationally-modified peptide antibiotics, is one such class of antibiotics that can 
complement current antibiotics for the treatment of Gram-positive MDR infections (9).  
Lantibiotics have been shown to have activity against drug-resistant Gram-positive 
pathogens, such as methicillin resistant Staphylococcus aureus (MRSA) (10-12). 
Furthermore, lantibiotics have been shown to have promising efficacy and 
pharmacokinetics in animal models (13-16). Most lantibiotics target lipid II, an essential 
component of cell wall biosynthesis. Lantibiotics, such as nisin and mutacin 1140, form 
a cage like structure around the pyrophosphate moiety of lipid II, the essential nature of 
this target leads to decreased chances in developing resistance (17). Together with its 
mode of action and broad spectrum of activity against Gram-positive bacteria, 
*
 Reprinted with permissions from Multipronged approach for engineering novel peptide analogues of 
existing lantibiotics by Jerome Escano and James Smith. 2015. Expert Opinion on Drug Discovery. 10:8. 
Copyright [2015] by Escano et al 2015 DOI: 10.1517/17460441.2015.1049527 
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lantibiotics have tremendous potential for their development as a therapeutic against 
MDR infections. Furthermore, the development of lantibiotic producing microbial 
strains as probiotics is another application of lantibiotics (18), such as the use of 
Streptococcus salivarius and Streptococcus mutans strains (19, 20). Streptococcus 
mutans, producer of mutacin 1140, is used in a technology referred to as replacement 
therapy to prevent dental caries. This therapy is aimed at reducing disease causing oral 
bacteria by supplementing the microbial niche with a non-disease causing genetically 
engineered strain of S. mutans (21, 22).   
Nisin was the first lantibiotic to have its covalent structure characterized. Since 
the structural characterization of nisin, a vast diversity of lantibiotic structures has been 
reported (23-27).  The lantibiotic core peptide generally contains several 
posttranslational modifications (PTMs) and is aptly named due to the presence of 
lanthionine residues (Figure 1.1A). All lantibiotics prior to cyclization, possess 2,3-
didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb), which are dehydrated serines 
and threonines, respectively. During cyclization, Dha or Dhb residues are further 
modified by forming thioether linkages with neighboring cysteines to form lanthionine 
or methyllanthionine rings, respectively (Figure 1.1A). Individual types of lantibiotics 
can have further modifications, such as the AviCys residue found in class I epidermin 
group of lantibiotics, D-alanine in lacticin 3147, and β-hydroxy aspartate in cinnamycin 
(28-30). The vast majority of lantibiotics have a similar biosynthetic gene loci and 
nomenclature. Lantibiotics have traditionally been subdivided into three major classes, 
class I lantibiotics which use both LanB and LanC for lanthionine synthesis, class II 
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lantibiotics which use bifunctional enzyme LanM for lanthionine synthesis, and class III 
lantibiotics which include all lantibiotics that do not have any antibacterial function but 
rather a regulatory function. Recently, a new class of lantibiotics that utilizes a unique 
synthetase, LanL, has been further characterized as class IV lantibiotics (31). The vast 
majority of lantibiotics fall within the class I and class II classification. In general, LanA 
denotes the unmodified core peptide attached to its leader peptide. In class I lantibiotics, 
LanB is a dehydratase that dehydrates serines and threonines, and LanC is the cyclase 
which helps form lanthionine and methyllanthionine rings (Figure 1.1A). In class II 
lantibiotics, a single gene, lanM, expresses a single bifunctional enzyme that performs 
the function of both LanB and LanC. LanP is a serine protease which cleaves off the 
leader peptide after transport by the ABC transporter LanT in class I lantibiotics. In class 
II lanbiotics, LanT is a bifunctional protein with an additional protease domain. The 
proteolytic release of the core peptide from the leader peptide triggers the antibacterial 
activity of the core peptide (32). Most lantibiotics have the producer immunity proteins 
LanFEG, which have also been shown to act as a secondary transport system. In general 
most lantibiotic biosynthetic gene clusters contain a two-component histidine kinase 
regulatory system, LanR and LanK (33). Additionally, some lantibiotic systems, such as 
gallidermin, have an additional immunity gene, LanI. Further studies aimed at increasing 
our understanding of the genetics of lantibiotic biosynthesis along with an in depth 
understanding of the limitations in lantibiotic structural diversity will promote 
development of this class of interesting antimicrobials for therapeutic use. 
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Although lantibiotics are a promising class of novel therapeutics, development of 
lantibiotics such as nisin, has been hampered by limitations in production, low solubility, 
and the susceptibility of lanthionines to oxidation (34-36). Creating novel variants from 
existing lantibiotics can help solve this problem. Mainly three different strategies have 
been utilized to produce novel lantibiotics through engineering. (i) In vivo engineering 
involves creating lantibiotic variants that have increased activity by manipulating the 
biosynthetic gene cluster (37, 38). This strategy can also help engineer lantibiotic 
producing strains of bacteria to synthesize significantly more antibiotic (39-41). (ii) 
Chemical synthesis provides another avenue toward the production of lantibiotics. This 
strategy opens a wide array of choices of producing novel lantibiotics with synthetic 
modifications and non-proteinogenic amino acids (42). (iii) In vitro engineering/semi-
synthetic methods offer the advantage of producing semi-synthetic lantibiotics that retain 
the stereochemistry of the natural product, while being able to enhance the bioactivity at 
site specific locations (43). This strategy encompasses several methods, such as the 
incorporation of non-proteinogenic amino acids and site specific additions of functional 
groups to the mature lantibiotic (44). These three strategies show the flexibility and 
promise the lantibiotic field can offer in terms of producing novel and effective 
therapeutics to treat MDR infections. This review further explores different studies that 
have utilized these three strategies in generating novel lantibiotics. 
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Figure 1.1 Schematic of common lantibiotic structures and biosynthesis genes. A) 
Structures of common posttranslational modifications found in lantibiotics. B) 
Biosynthetic gene loci for different classes of lantibiotics. Orange genes indicate genes 
involved immunity. Green genes indicate genes involved in regulation. Yellow 
designates the gene for the lantibiotic product. Blue are genes involved in amino acid 
dehydration and lanthionine synthesis. Red encodes for the transporter. White encodes 
for the lantibiotic specific protease. 
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I.2. in vivo engineering of lantibiotics 
I.2.1 Class I lantibiotics 
 In bacterial systems that have the tools developed for genetic manipulation, 
enhancing the activity or production of lantibiotics by amino acid substitution provides 
an effective and relatively straight-forward method to create novel structural variants. In 
the past 10 years there have been a number of genetic engineering studies which have 
successfully been able to produce lantibiotic variants with increased activity. Nisin-
producing Lactococcus lactis has been successfully used for over 50 years in the dairy 
industry to prevent unwanted bacterial contamination (45). The class I lantibiotic, nisin, 
is responsible for its utility as an organic preservative and this application in food 
microbiology has promoted the study of nisin (46). Therefore, there are several 
mutagenesis studies leading to the production of novel variants of nisin. A substitution 
of threonine in position 2 for a serine increased activity of nisin against multiple strains 
tested (Figure 1.2A) (47). This mutation also led to the dehydration of this serine 
indicating promiscuity of the dehydration for some amino acid substitutions. Some 
amino acid substitution mutants, such as the substitution of three amino acids in ring A 
had shown enhanced activity (Figure 1.2A) (48).  Furthermore, the VFG variant had 
decreased activity against other indicator strains but had increased activity against the 
producing strain, indicating loss of host immunity protection. This is an important 
finding given that resistance mechanisms found in clinical isolates often share enzymatic 
resistance mechanisms found in producing strains. The study demonstrates that it is 
possible to modify the lantibiotic peptide in a manner that may prevent the selection and 
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clinical development of producer strain resistance. In some class I lantibiotics, such as 
nisin and mutacin 1140, rings A and B are essential for binding to the pyrophosphate 
moiety of its cellular target lipid II (49-52). Initial binding to lipid II’s pyrophosphate 
moiety is through the NH backbone of rings A and B, thus amino acid substitutions in 
Rings A and B could potentially stabilize or increase affinity to lipid II. A saturation 
mutagenesis study on nisin led to the discovery of additional variants with enhanced 
bioactivity. In the hinge region of nisin, between ring B and C, the substitution K12A 
had shown an increase in activity (53). Single amino acid substitutions in another nisin 
hinge region between rings C and D also enhanced activity against multiple strains tested 
(Figure 1.2A) (54-56). Interestingly, there is a structural diversity within the hinge 
region of other natural peptide analogs of nisin. Thus, it was expected that structural 
variants within the hinge region could be isolated. The identification of natural variants 
of lantibiotics is important for identifying structural regions that are amenable to amino 
acid substitutions. The mutation S29G in nisin had a 2-fold increase in MIC against 
selected pathogens (57). In the related class I peptide mutacin 1140, a single amino acid 
substitution at W4A in ring A had a significant increase in activity against several Gram-
positive strains tested, including the pathogenic strain Clostridium difficile (Figure 1.2A) 
(40). The R13D mutant in the hinge region of mutacin 1140 had the largest zone of 
inhibition activity, but the purified product had a significant reduction in activity. Thus, 
this mutation was expected to have promoted the production of the R13D variant 
compared to the wild type variant (40). The substitution to an aspartic acid may have 
interfered with the regulation of mutacin 1140 production or possibly increased the 
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peptide's stability. Class II lantibiotics are structurally distinct from class I lantibiotics 
and the structural regions that promote bioactivity are also uniquely different. 
 
I.2.2 Class II lantibiotics 
Aside from utilizing the bifunctional enzyme, LanM, class II lantibiotics 
generally have a more globular structure compared to class I lantibiotics (33). In the past 
6 years, multiple studies have been able to produce enhanced variants of existing class II 
lantibiotics. The most well-known and studied of class II lantibiotics is mersacidin. It is 
naturally produced by Bacillus sp. HILY-84,54728, but has had its biosynthesis genes 
moved into the naturally competent Bacillus amyloliquefaciens FZB42 strain (58, 59). In 
a saturation mutagenesis study for mersacidin, only the mutation F3W increased activity 
against the medically important bacteria S. aureus and S. epidermidis (Figure 1.2B). 
Other mutations in mersacidin had enhanced activity, but only against a few of the 
bacterial strains tested (60). Saturation mutagenesis was performed on a similar 
lantibiotic, actagardine A, produced by Actinoplanes garbadinensis ATCC 31049. One 
mutant, V15F had increased activity against some pathogenic strains, such as 
Streptococcus pneumoniae (Figure 1.2B) (61). Nukacin-ISK1, produced by 
Staphylococcus warneri ISK1, is another class II lantibiotic that has been bioengineered 
to produce enhanced variants. Two single substitution mutants, D13E and V21I were 
able to enhance activity (Figure 1.2B) (39). The reason for the increase in bioactivity is 
not readily apparent, given the similarity between the amino acid substitutions. The 
aspartic acid residue at position 13 is located in ring A of nukacin-ISK1. The mutation to 
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a similarly charged glutamic acid may promote access or affinity to lipid II. In both class 
II lantibiotics, mersacidin and actagardine, a negatively charged residue at this position 
is conserved, indicating importance of this negatively charged residue for class II 
lantibiotics (62). Zendo et al hypothesized that the substitution of valine at position 21 to 
a bulkier isoleucine may limit the peptide rotation when bound to target, thus, increasing 
its affinity. Mutations in the histidine at position 15 did not increase activity for the 
purified nukacin-ISK1, but had increased lantibiotic production by almost 4-fold 
compared to wild type (39). The two component lantibiotic lichenicidin, normally 
produced by Bacillus licheniformis DSM13, had its biosynthesis pathway fully 
reconstituted into a Gram-negative host E. coli. The transfer of the biosynthetic pathway 
promoted mutagenesis studies that enabled the characterization of essential structural 
elements within the two component system (63). An alanine scanning mutagenesis study 
on the two component lantibiotic lacticin 3147, produced by L. lactis subsp. lactis 
DPC3147, was performed and only one of the substitutions increased activity but has not 
been tested against multiple strains (Figures 2C) (64). Producing enhanced variants of 
two-component lantibiotics is much more challenging given that two lantibiotic peptides 
work together in synergy. Recently, a single variant in lacticin 3147 Ltnα in which the 
histidine at position 23 was substituted with a serine had an increase in activity against a 
pathogenic strain of Staphylococcus aureus (65). 
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I.2.3 Increasing yield through in vivo engineering 
 Low fermentation and isolation yields for many lantibiotics has hampered the 
development of lantibiotics as a feasible therapeutic. In vivo engineering of the 
producing strains offers a method to increase yields of lantibiotics. Amino acid 
substitutions have been shown to increase production of some lantibiotics. Mutations in 
the histidine at position 15 of nukacin-ISK1 did not increase activity for the purified 
product, but had increased lantibiotic production by almost 4-fold compared to wild-
type. Similarly, the mutation R13D in mutacin 1140 reduced activity, but had 
significantly increased yields. Panke et al used a modified strain of Staphylococcus 
gallinarum Tü3928 along with stress conditions to induce higher yields of gallidermin. 
This modified S. gallinarium strain produced a variant of gallidermin with the leader 
peptide attached, which prevented self-toxicity of the mature lantibiotic (41, 66). In 
addition, the subjection of some lantibiotic producing strains to stressful conditions can 
increase production yields compared to normal growth conditions (67-70). 
Overexpression of nisin and PTM enzymes using inducible promoters has supported 
studies on nisin. The nisin induced expression system has been used for over a decade 
for the production of nisin (71). Likewise, production of nisin was significantly 
increased compared to the normal producing strain by the optimization of a nisin 
overexpression cassette (72). Conversely, some lantibiotics are difficult to produce and 
genetically manipulate due to the nature of the producing strain. Lantibiotics, such as 
nukacin-SK1 and mersacidin have been heterologously produced in other bacterial 
species, not only to increase yields but to facilitate mutagenesis experiments (39, 58, 73). 
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To further expand lantibiotic production tools, heterologous expression in E. coli has 
been attempted for various class II lantibiotics (63, 74-76). A successful example of 
heterologous expression in E. coli is for the lantibiotic lichenicidin. Studies that promote 
the production and isolation of lantibiotics in combination with studies that enhance their 
bactericidal activity will further the development of lantibiotics for commercial 
applications. 
In vivo engineering of lantibiotics has produced variants with enhanced activity 
or production. This method is relatively simple and efficient way to create large libraries 
of lantibiotic analog. However, in vivo engineering has its limits given that the PTM 
enzymes generally do not accommodate all amino acid substitutions, thus, not all 
positions can be modified. This is generally observed at amino acid positions that disrupt 
lanthionine formation, ring size, or lanthionine location (77). Furthermore, the lantibiotic 
producer strain usually has some limitations, such as low yields of production and lack 
of genetic manipulation tools. Most in vivo engineering studies focus on increases in 
activity of the purified lantibiotic variants, but fail to report notable changes in yields. 
Alternative methods, such as chemical synthesis can help overcome these limitations. 
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Figure 1.2 Structures and modifications of lantibiotics enhanced through in vivo 
engineering,  A) Class I lantibiotics; Mutacin 1140 and Nisin (40, 53), B) Class II 
lantibiotics; Nukacin – ISK1, Mersacidin and Actagardine (39, 60, 61), C) Two-
component lantibiotics, Lacticin 3147 – Ltnα ans Lacticin 3147 – Ltnβ (64, 65). Unusual 
amino acids are labeled as such: Dha: 2,3-didehydroalanine, Dhb, 2,3-
didehydrobutyrine, Ala-S-Ala: lanthionine ring, Ala-S-Abu: methyllanthionine ring, D-
Ala: D-alanine, 2-ob: 2-oxobutyrate. Arrows designate amino acid substitution within 
the native lantibiotic structure. Amino acid substitutions colored in red resulted in an 
increase in activity. Substitutions in green resulted in an increase in lantibiotic 
production. Substitutions in blue designate multiple amino acids substitutions within the 
core peptide that resulted in an increase in activity. 
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I.3. Chemical synthesis of lantibiotics 
I.3.1 Synthesis of native lanthionines 
Chemical synthesis of lantibiotics bypasses the limitations of the modification 
machinery, and allows for greater variety of analog to be produced. Furthermore, this 
allows for the incorporation of non-proteinogenic amino acids, which can promote the 
generation of large structural libraries that can be screened for improvements in activity. 
Although promising, chemical synthesis of lantibiotics poses a unique challenge to 
chemists due to the extent of posttranslational modifications found within lantibiotic 
peptides. For a long period of time, a solution chemical synthesis route of nisin was the 
only successful instance of producing a full length lantibiotic (78). This analog of nisin 
had the same activity as natural nisin against a broad range of Gram-positive bacteria, 
including some pathogenic strains. However, the overall yield from this approach was 
low and the method did not afford a viable approach for production. Due to recent 
advances in solid phase peptide synthesis (SPPS), many other lantibiotics have been 
chemically synthesized. The synthesis of orthogonally protected methyl/lanthionine 
rings has allowed for tremendous advances in lantibiotic chemical synthesis (Figure 
1.3A) (79-81).  
SPPS of lantibiotics was first limited to lantibiotics containing non-overlapping 
lanthionine rings. Over a decade after the synthesis of nisin by a solution chemical 
synthesis route, lactocin S was the first full length lantibiotic to be produced using SPPS 
(82). This synthetic analog had similar activity as the natural variant in a spot lawn assay 
against Pediococcus acidilactici Pac 1.0.  Furthermore, a variant of lactocin S with the 
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non-proteinogenic amino acid norleucine at the methionine 12 position had enhanced 
activity (Figure 1.3B) (83). The substitution of methionine for a norleucine was done to 
prevent oxidation at this position. A challenge for many other lantibiotics is the presence 
of overlapping lanthionine rings, as is the case for rings DE in nisin. The synthesis of 
additional building blocks with differentially protected orthogonal lanthionine groups 
helped overcome the restriction of synthesizing lantibiotics containing overlapping 
lanthionine rings (Figure 1.2) (84).  In the two component lantibiotic lacticin 3147, both 
peptide components have been chemically synthesized (84). This study was the first 
instance of using Fmoc SPPS technology in creating overlapping lanthionine rings. 
When paired with their natural counterparts, the synthetic lacticin 3147 components had 
virtually indistinguishable synergistic activity. The synthetic lacticin 3147 also had no 
activity against the natural producing strain, indicating recognition of the synthetic 
peptide by the bacterial immunity factors. The chemical synthesis of lacticin 481 was 
more challenging due to the presence of three overlapping rings in its structure (85). In 
this study, analogs of lacticin 481 were produced with aberrant lanthionine LL 
stereochemistry instead of the normal DL stereochemistry. The DL lacticin 481 analog 
had similar activity to the natural lantibiotic, while the LL diastereomers had no activity. 
The lack of activity demonstrates the importance of the lanthionine stereochemistry for 
bioactivity. Chemical synthesis of epilancin 15X, produced by S. epidermis 15x154, was 
used to determine the importance of the lantibiotic’s N-terminal region (86). Epilancin 
15X rings BC are homologous to rings DE in nisin. The N-terminal region of epilancin 
15X does not have the lipid II binding domains found in nisin's rings AB. The full length 
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synthetic variant of epilancin 15X had similar activity to the natural variant, but the 
truncated form (Δ1-8) had a hundred-fold reduction in activity against the indicator 
strain S. carnosus. The ability to synthesize even overlapping lanthionine rings shows 
the tremendous progress in the field of lantibiotic chemical synthesis. Chemical 
synthesis of lantibiotics, even with multiple complicated synthesis steps, has a total 
synthesis yields between 2% to 10% (82-86).   Direct comparisons between natural 
product isolation and chemical synthesis have not been adequately addressed in the 
literature. Complete synthesis of lantibiotics has allowed researchers to develop new 
methods to produce lantibiotics containing lanthionine mimics. 
 
I.3.2 Synthesis of lanthionine mimics 
 Oxidation of the lanthionines in nisin was shown to abolish both binding to lipid 
II and activity (34). This observation could prove similar to other lantibiotics, effectively 
limiting their application. Conversely, only one single lantibiotic has been shown to have 
a naturally oxidized lanthionine ring. The last ring in actagardine is composed of an 
oxidized lanthionine ring, which has been shown to be important for both the activity 
and solubility of the lantibiotic (87, 88). To prevent oxidation of the sulfur group, 
multiple groups have attempted to substitute the lanthionine ring with alkene, alkane, or 
even oxygen groups (Figure 1.3C). This was attempted in producing ring AB and ring 
ABC variants of nisin with either alkene or alkane bonds using ring-closing metathesis 
(Figure 1.3C) (89, 90). These fragments were tested for binding to lipid II and none of 
these variants could bind to lipid II with the same affinity as the natural fragments. Rings 
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DE alkene mimics were also synthesized but could not be tested fully due to the 
requirement of rings AB for binding to lipid II (89, 91). A ring expanded alkene variant 
of lacticin 3147 Ltnβ was produced by SPPS (92). This variant had no activity by itself 
and lacked synergy with lacticin 3147 Ltnα. Further lanthionine modifications in lacticin 
3147 Ltnβ were made in which the lanthionine sulfurs were substituted with oxygens. 
The oxygen variant of lacticin 3147 Ltnβ had significantly lower intrinsic activity, and 
the variant could not work synergistically with lacticin 3147 Ltnα. In addition, a variant 
containing only lanthionine rings instead of methyllanthionine rings was created, 
referred to as (Bis(desmethyl) Ltnβ (Figure 1.3C) (93, 94). In contrast to the oxygen 
variant, the bis(desmethyl) variant lost intrinsic activity, but retained its synergistic 
activity with lacticin 3147 Ltnα . In lactocin S, the ring A lanthionine was substituted 
with a lanthionine mimic diaminopimelate (DAP). This substitution in lactocin S 
retained full activity against P. acidilactici Pac 1.0 (Figure 1.3C) (95). This study does 
demonstrate that lanthionine mimics in some systems could retain activity. However, the 
activity of many of the lanthionine mimics is lower compared to its natural counterpart. 
These observations do suggest that the lanthionine ring is important for optimal activity 
of lantibiotics. However, given the susceptibility of lanthionines to oxidation, methods 
and studies to identify lanthionine mimics to circumvent potential oxidation problems 
should continue to be explored. 
 Chemical synthesis allows researchers to bypass the limits of ribosomal synthesis 
of lantibiotics. The successful chemical synthesis of a variety of lantibiotics paves the 
way for further studies aimed at promoting the development of lantibiotics for treating 
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infectious diseases. Chemical synthesis provides advantages over in vivo production by 
enabling the synthesis of new structural analogs and facilitates higher yields of product 
when the producing strain is not capable of making sufficient quantities. Currently, the 
structural analogs of lantibiotics produced by SPPS are relatively small and further 
studies involving the incorporation of conventional and non-proteinogenic amino acids 
have not been adequately screened for improvements in activity. The bioactivity studies 
have been limited to only a few indicator strains. Additionally, the incorporation of all 
the unique PTMs found in lantibiotics have not been demonstrated by a SPPS approach, 
for instance the AviCys residue found in the epidermin group of lantibiotics have not yet 
been reported. Furthermore, there is still a need to optimize the synthesis of the 
orthogonal lanthionine rings for their integration into conventional SPPS approach for 
promoting a financially viable method to making lantibiotics. Semi-synthetic methods of 
production could combine the strengths of both chemical and in vivo production of 
lantibiotics. 
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Figure 1.3 Representation of synthetic lantibiotic building blocks and fully synthesized 
lantibiotic variants. A) Chemical structures of commonly used orthogonally protected 
lanthionines (79-81). Abbreviations of side chains are: Fmoc: 
fluorenylmethyloxycarbonyl, Aloc: allyloxycarbonyl, and pNb: p-nitrobenzyl. B) 
Chemically synthesized variant of lactocin S with norleucine substituted at position 12
 
(83). C) Covalent structures of lantibiotics chemically synthesized with lanthionine 
mimics or lanthionine substitutions (89-95). The modifications are highlighted in red. 
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I.4. in vitro biosynthesis of lantibiotics  
I.4.1 in vitro mutasynthesis 
 In vitro synthesis is another method wherein enhanced analogs of lantibiotics can 
be produced. Producing lantibiotics by an in vitro method bypasses several potential 
problems that may occur in an in vivo expression system. For instance, enhancement of 
lantibiotic activity may be toxic to the producing strain, thus, restricting these types of 
studies. Furthermore, some variants may not be efficiently synthesized by the producing 
strain and would hinder their isolation and bioactivity characterization studies. In vitro 
synthesis of lantibiotics, especially for class I lantibiotics is challenging due to using 
multiple enzymes for complete biosynthesis. In class II lantibiotics, the presence of the 
single bifunctional enzyme LanM makes in vitro synthesis less complicated (Figure 1.1). 
Furthermore, studies into the kinetics of various LanM enzymes could lead to the 
successful application of LanM synthetases to other peptides (96, 97).The successful in 
vitro synthesis of a lantibiotic has led to the development of an in vitro technique 
referred to as mutasynthesis, wherein chemically or ribosomally synthesized precursor 
peptides are modified by in vitro reconstituted lantibiotic synthetases. The production of 
enhanced analogs of lacticin 481 has been accomplished using in vitro mutasynthesis. 
Analogs of lacticin 481 were created by first making lacticin precursor peptides by SPPS 
containing non-proteinogenic amino acids, the PTM containing lanthionine rings were 
subsequently introduced in vitro by using the bifunctional enzyme LacM (43, 98). Of the 
11 analogs containing non-proteinogenic amino acids, two were found to have enhanced 
antibacterial activity. The substitution of either a homophenylalanine or a napthylalanine 
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resulted in a significant increase in activity. In another lantibiotic system, in vitro 
reconstitution of both HalM1 and HalM2 enzymes for the two component lantibiotic 
haloduracin A1 and haloduracin A2 allowed for structural and mode of action studies to 
be performed on these peptides (99, 100). Although promising, in vitro mutasynthesis 
has been limited to class II lantibiotics. Given current developments in reconstructing in 
vitro activities of class I synthetase LanB, the synthesis of class I lantibiotics by in vitro 
mutasynthesis will be accomplished soon (101). Both the structures of NisC and NisB 
have been elucidated, which could potentially lead to the in vitro synthesis of class I 
lantibiotics (102, 103). The synthesis of biologically active nisin using bacterial extracts 
has been previously shown, thus, the use of purified PTM enzymes should be possible 
(104).   
 
I.4.2 Lantibiotic Coupling (Semi-synthetic) 
 Coupling of lantibiotics provides another opportunity to make novel peptide 
variants enabling new applications and functions. The potential applications of this 
approach include the development of target specific bacterial probes, expanding the 
bioactivity of the lantibiotic, and provide a protective layer by coating lantibiotics on 
medical equipment (105, 106). The conjugation of lantibiotics with various compounds 
has been the subject of several studies. For instance, conjugating nisin with select 
functional groups has the potential for producing more stable and soluble analogs. 
PEGylation of nisin was attempted, but this approach led to inactive analogs  due to the 
acylation of the lysine residues on nisin (105). Conversely, biotinylation of the C-
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terminus of nisin by EDC coupling resulted in a functional analog that retained activity 
against Kocuria rhizophilia (107). N-terminally thiolated nisin variants with 
poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide) triblocks have been 
synthesized (108). These coupled variants of nisin exhibited similar activity to wild-type 
nisin. Since the nisin AB rings are important for lipid II binding, this truncated form of 
nisin has been utilized for forming antibiotic hybrids that may promote dual 
functionality for binding antimicrobial targets. Nisin AB (1-12) was conjugated to 
vancomycin using click chemistry (109). Since both antibiotics targeted lipid II, albeit at 
different regions of lipid II, it was hypothesized that binding nisin to vancomycin would 
increase the variants affinity for lipid II and ultimately increase activity against 
vancomycin resistant strains. The nisin (1-12)–vancomycin hybrid was shown to restore 
activity against vancomycin resistant enterococci than vancomycin (109). Previously, as 
described above, an alkene substituted ring DE fragment of nisin could not be tested due 
to the requirements of rings AB for binding to lipid II. Using the same click chemistry 
method, the alkene rings DE were fused to nisin's rings ABC to determine the effects of 
the alkene substitution on these rings (110). Unfortunately, the DE nisin hybrid variant 
did not exhibit pore formation activity nor did it promote binding to lipid II. To help 
facilitate conjugation of nisin at the C-terminus, a variant containing a C-terminal alkyne 
was developed to promote conjugation of various azide containing molecules by click 
chemistry. Initial conjugation with fluorophores yielded nisin conjugates that retained 
activity (106). In an attempt to potentially expand the spectrum of activity of lantibiotics 
to Gram-negative bacteria, gallidermin lysine residues were conjugated with various 
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siderophores. It was believed that the conjugated siderophores would facilitate the 
transport of gallidermin across the outer membrane. Although, the conjugates retained 
activity against the Gram-positive indicator strain L. lactis subsp. cremoris HP, the 
conjugated variants did not yield any activity against Gram-negative bacteria (111). 
NVB302 is a semi-synthetic variant of deoxyactagardine with a synthetically introduced 
C-terminal 1, 7 diaminoheptane tail (112). This variant has been shown to have greater 
solubility and activity compared to deoxyactargardine. NVB302 is being developed for 
the treatment of C. difficile and is currently in a phase I clinical trial, successfully 
showing a semisynthetic variant of an existing lantibiotic can be developed for further 
uses (113).  
 In vitro mutasynthesis and lantibiotic conjugation offer unique opportunities to 
engineer enhanced variants of lantibiotics or facilitate new lantibiotic applications. In 
vitro mutasynthesis combines both the strengths of chemical synthesis with the ease and 
practicability of using the PTM enzymes. Unfortunately, in vitro mutasynthesis is 
currently limited to producing class II lantibiotics. The conjugation experiments of 
lantibiotics could potentially broaden the scope of lantibiotic applications. However, 
conjugation experiments have generally led to a decrease in lantibiotic activity. The 
conjugate may be interfering with lantibiotic’s ability to access or bind to its target. The 
chemical substitutions may perturb important functional elements within the lantibiotic. 
The combination of conjugation methods and SPPS by conjugating SPPS building 
blocks may enable the creation of larger structural libraries that can be screened for 
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improvements in activity. For now, the challenge of lantibiotic conjugation is a balance 
between retaining activity and introducing a new or enhanced function.  
 
I.5. Conclusions 
The three different methods: (i) In vivo engineering of variants through amino 
substitutions, (ii) incorporation of proteinogenic and non-proteinogenic amino acids or 
lanthionine mimics through complete chemical synthesis or in vitro mutasynthesis, and 
(iii) chemical coupling of lantibiotics are useful in the development of novel lantibiotics. 
These techniques have furthered our understanding of structurally important regions for 
activity and have also led to the development of lantibiotic variants with an increase in 
inhibitory activity against medically relevant bacterial pathogens. The multipronged 
approaches for engineering novel lantibiotics have expanded our understanding of 
lantibiotic function and have provided evidence that they are all useful methods for 
improving the spectrum of activity of current lantibiotics. 
 
I.6. Future directions 
 Lantibiotics are active against a broad spectrum of Gram-positive bacteria, 
including multi-drug resistant pathogens. Several different approaches for producing 
novel lantibiotic analogs have demonstrated their potential for developing lantibiotics 
with improved in vitro inhibitory activities against pathogenic bacteria. However, some 
of the reports on the bioactivity of novel lantibiotic analogs were limited. For instance, 
several studies performed on nisin only tested the activity against a few strains of 
 24 
 
pathogenic and non-pathogenic bacteria (53-55, 57). Rescreening the activity of these 
structural variants against a full spectrum of medically relevant Gram-positive bacteria 
may elucidate the analog's medical application. A more in-depth understanding of the 
variation in the activity of these analogs against a larger spectrum of bacteria may 
promote site-specific engineering studies that can further improve their activity against 
specific bacterial species. In addition, some of the analogs that were considered to have a 
reduction in activity may actually have superior activity against bacteria in a larger 
screen. The reasoning for the increase in activity of these structural analogs against 
different bacteria is not understood. Additional studies aimed at understanding whether 
the modification promotes binding to the microbial target need to be done. For instance, 
lipid II is the biological target for many of the class I and class II lantibiotics. If some of 
the structural modifications improve lipid II affinity or access to lipid II, this information 
may lead to an improved approach for producing enhanced analogs.  
The efforts up to now have been an erudite exercise demonstrating that 
lantibiotics can be synthesized with activities superior to the native compounds. These 
approaches have not yet been fully applied toward the development of a new lead 
compound for clinical development. Many factors need to be taken into consideration for 
the development of a lead compound. The half-life and distribution of an antimicrobial 
compound is just a couple of important factors that need to be addressed. The half-life of 
lantibiotics like nisin and mutacin 1140 are relatively short (14, 36). To date, there have 
not been any reports showing improvements in the pharmacokinetic activities of 
lantibiotics. These studies will be more significant than the reported improvements in the 
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inhibitory activity against Gram-positive pathogens, given that lantibiotics already have 
submicromolar and nanomolar activities.  The in vivo and synthetic methods aimed at 
expanding lantibiotic function were all done on relatively small analog libraries. With 
this realization, significant efforts have hardly even begun until studies begin to explore 
the full breadth of proteinogenic and non-proteinogenic amino acid substitutions. These 
studies should not only take into consideration microbial inhibitory activity, but also 
activities that will improve the pharmacokinetic and pharmacodynamic activities of the 
native compound. 
Commercially viable methods for large scale synthesis are a limiting factor for 
several lantibiotics and are a major problem that has hampered the development of 
lantibiotics for therapeutic use. Even though some of the in vivo synthesized analogs did 
significantly increase lantibiotic production, E. coli expression or chemical synthesis 
may be the best method to produce lantibiotics in large scale. In vivo engineering can be 
cumbersome due to numerous issues, such as the lack of genetic tools and the lack of 
growth conditions for producing the lantibiotic. The movement of the biosynthesis genes 
to a heterologous expression host could circumvent these problems. In the review, we 
did mention the expression of lichenicidin in E. coli and the expression of mersacidin in 
a genetically competent bacilli species. The movement of other lantibiotic biosynthesis 
genes into a heterologous expression host has been accomplished and using this 
approach for other lantibiotic systems may improve their production and bioactivity 
characterization studies. However, E. coli expression systems for lantibiotics are limited 
to the complexity of the biosynthesis pathway for the lantibiotic and have limitations in 
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lantibiotic transport. A commercially viable production of lantibiotics using an E. coli 
system has not yet been reported. Recently, Süssmuth et al have been able to isolate 
lichenicidin from E. coli, but yields were still low enough to be considered nonviable 
(114). In vitro mutasynthesis is still relegated to class II lantibiotics, but has the potential 
to synthesize class I lantibiotics. Furthermore, in vitro mutasynthesis can be used to 
modify other non-lantibiotic peptides, which may also facilitate the production of unique 
peptides with nonantimicrobial applications (115-117). The relative stability or 
robustness of the PTM enzymes, as well as the yield of fully modified peptides from the 
in vitro mutasynthesis approach have not been adequately reported. Although promising, 
chemical synthesis of lantibiotics requires a profusion of protection and de-protection 
steps. Improvements in these chemical steps may facilitate commercially viable yields of 
lantibiotics.  
 Advances in next generation sequencing and techniques for cultivating hard to 
grow bacteria will facilitate the discovery of new lantibiotics. Some of these lantibiotics 
may reveal novel PTM modifications and structures. Although a vast majority will 
probably be related to currently known lantibiotics, the differences in amino acids 
compositions within these naturally occurring analogs will point toward regions that are 
amenable to modification. The knowledge of these naturally variable regions will assist 
in facilitating studies at promoting lantibiotic function. Multiple methods of producing 
novel lantibiotic analogs have increased the scope of our understanding of lantibiotic 
structure and function. These methods have also promoted the potential for lantibiotics 
to augment our current repertoire of clinically used antibiotics.  
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CHAPTER II:                                                                                                              
THE LEADER PEPTIDE OF MUTACIN 1140 HAS DISTINCT STRUCTURAL 
COMPONENTS COMPARED TO RELATED CLASS I LANTIBIOTICS
*
 
II.1. Synopsis 
Lantibiotics are ribosomally synthesized peptide antibiotics composed of an N-
terminal leader peptide that promotes the core peptide's interaction with the PTM 
enzymes. Following PTMs, mutacin 1140 is transported out of the cell and the leader 
peptide is cleaved to yield the antibacterial peptide. Mutacin 1140 leader peptide is 
structurally unique compared to other class I lantibiotic leader peptides. Herein, we 
further our understanding of the structural differences of mutacin 1140 leader peptide to 
other class I leader peptides. We have determined that the length of the leader peptide is 
important for the biosynthesis of mutacin 1140. We have also determined that mutacin 
1140 leader peptide contains a novel four amino acid motif compared to related 
lantibiotics. PTM enzyme recognition of the leader peptide appears to be evolutionarily 
distinct from related class I lantibiotics. Our study on mutacin 1140 leader peptide 
provides a basis for future studies aimed at understanding its interaction with the PTM 
enzymes.  
 
  
                                                 
*
 Reprinted with permissions from The leader peptide of mutacin 1140 has distinct structural components 
compared to related class I lantibiotics by Jerome Escano, Byron Stauffer, Jacob Brennan, Monica 
Bullock, and James Smith. 2014. MicrobiologyOpen. 3:6. Copyright [2014] by Escano et al 2014 DOI: 
10.1002/mbo3.222 
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II.2. Introduction 
Many strains of medically important bacteria have become increasingly resistant 
to currently available antibiotics.  Healthcare associated infections caused by multi-drug 
resistant pathogens are leading to longer hospital stays and increased mortality. 
Worldwide, millions suffer from antibiotic-resistant infections, which results in a huge 
cost to the healthcare system. The development of new antibiotics has become a critical, 
unmet need in the medical community (118-120). Lantibiotics are an important class of 
antibiotics with potential clinical relevance for the treatment of antibiotic resistant Gram-
positive bacteria (81, 121-123). Lantibiotics acquired their name because of the 
characteristic lanthionine rings found in the bioactive core peptide. Lantibiotics also 
contain an array of unusual amino acids such as Dha, Dhb, AviCys, aminobutyrate 
(Abu), 2-oxopropionyl, 2-oxobutyryl, and hydroxypropionyl (81, 121-123). The 
molecular structure of mutacin 1140 contains four macrocyclic rings (see Figure 2.1A), 
each of which contains a lanthionine or methyllanthionine residue. Mutacin 1140 also 
contains the posttranslational modified amino acid residues Dha, Dhb, and AviCys (29). 
Mutacin 1140 rings A and B (Figure 1A), the lipid II binding domain, is similar to the 
class I lantibiotics nisin and epidermin (24). It was discovered that both nisin and 
mutacin 1140 abduct lipid II from the site of new cell wall synthesis, ultimately causing 
cell death (51, 52). 
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Figure42.1 Lantibiotic structural elements. A) Covalent structures for mutacin 1140, 
epidermin, and nisin with the lanthionine rings labeled from N- to C-terminus. B) Leader 
sequence alignments of structurally related class I type AI lantibiotics; i.e. mutacin 1140 
produced by S. mutans, nisin produced by L. lactis, subtilin produced by B. subtilis, 
epidermin produced by S. epidermidis, gallidermin produced by S. gallinarium, Pep5 
produced by S. epidermidis, epilancin K7 produced by S. epidermidis (23, 124, 145-
150). C) Secondary structure prediction using SOPMA for mutacin 1140 leader peptide; 
h (alpha helix), e (extended strand), c (random coil), t (beta turn). Alpha helical regions 
are in bold, while random coils are underlined in the leader peptide sequence. 
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Mutacin 1140 is synthesized by the Gram-positive oral bacterium Streptococcus 
mutans JH1140 (124). Mutacin 1140 was shown to have low micromolar to 
submicromolar minimum inhibitory concentration (MIC) against several species of 
Gram-positive pathogens (10). The study by Ghobrial et al. further demonstrated that 
mutacin 1140 is bactericidal against Streptococcus pneumoniae and multi-drug resistant 
strains of Staphylococcus aureus, bacteriostatic against vancomycin-resistant 
Enterococcus faecium (VREF), and had no activity against Gram-negative bacteria or 
yeast. The study demonstrated that mutacin 1140's time-kill profile against select 
pathogens was similar to those of vancomycin, which also binds to lipid II (125). 
Furthermore, mutacin 1140 had a low in vitro cytotoxicity, was well tolerated in murine 
models when administered intravenously, and was found to be distributed in all body 
compartments.  Demonstration of efficacy was achieved in a pilot study in which 60 
times the LD50 of Staphylococcus aureus was administered in a rat peritonitis model 
(14). Development of significant resistance was not observed during repeated subculture 
of S. aureus or S. pneumoniae in medium containing sub-lethal concentrations of 
mutacin 1140 (10). The basis for this observation may be due, in part, to the fact that the 
molecular target, the isoprene, pyrophosphate, and N-acetylmuramic acid of lipid II, is 
evolutionarily ancient and highly conserved throughout the bacterial kingdom, indicating 
that mutations within this structural element of lipid II may be prohibited.  Based on 
these and other studies, mutacin 1140 has the potential to replace current, failing drugs 
of last resort and serve in the treatment of problematic infections caused by Gram-
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positive bacteria such as methicillin resistant S. aureus, vancomycin resistant 
Enterococci, and Clostridium difficile. 
A better understanding of the biosynthesis of mutacin 1140 may promote the 
production and purification of mutacin 1140 or core peptide variants of mutacin 1140. 
Several core peptide variants of mutacin 1140 have been previously engineered to have 
enhanced bioactivity (40). The mutacin 1140 leader peptide sequence is distinct from the 
leader peptide of related class I lantibiotics (Figure 2.1B). Class I leader peptides have 
conserved structural elements. The common motif found in class I lantibiotics is the 
F(N/D)LD box and a proline at the (-2) position. Several mutagenesis studies with the 
lantibiotic nisin biosynthesis system show that the box motif is important for the 
maturation of the core peptide antibiotic (126-128). Additional experimental studies 
suggest that the leader peptide is important for interacting with the dehydratase LanB, 
cyclase LanC, and transporter LanT (117, 129, 130). However, these studies are 
challenged by the failure to distinguish between which of the proposed leader peptide 
functions are affected by the changes in amino acid residues.  
 In this study, we have identified structural regions in the leader peptide that are 
important for the biosynthesis of mutacin 1140 core peptide. We have determined that 
the leader peptide function is not dependent on the amino acid sequence except for a four 
amino acid region within the center of the leader peptide. These four amino acids 
comprise a novel four amino acid motif with the latter two amino acids being essential 
for leader peptide function. This motif is different in amino acid properties found in 
other class I lantibiotic motifs in related lantibiotic groups such as nisin and epidermin. 
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Mutacin 1140 leader peptide is also longer than other class I lantibiotic leader peptides 
and we have determined that the additional length of the peptide of mutacin 1140 is 
important for efficient biosynthesis. These studies advance our understanding of the 
biosynthesis of mutacin 1140 and will promote future studies aimed at furthering our 
understanding of the leader peptide's interaction with the PTM modification enzymes.  
 
II.3. Results 
II.3.1 Length of the leader peptide affects biosynthesis 
 The mutacin 1140 leader peptide (Figure 2.1B) is 18 and 11 amino acids longer 
than nisin A and epidermin leader peptides, respectively. Small consecutive truncations 
of four and five amino acids were made starting at the (-40) position corresponding to 
the amino acid after N-terminal methionine (Figure 2.2A). Deletion mutations between 
residues Δ(-40 to -37), Δ(-36 to -33), Δ(-32 to -28) were investigated to determine 
whether there are regions of structural importance in the extended leader peptide (Figure 
2A). These mutations had little impact on the bioactivity of the mutant strains as 
determined by deferred antagonism assays (Figure 2.2B). This assay is a sensitive 
quantitative measurement of bioactivity for mutacin 1140 production (40). Each strain of 
S. mutans is grown under identical conditions and the bioactivity is assessed by 
calculating the percent differences in the area of the zone of inhibition between mutant 
strains and wild-type strain. Reductions in activity suggest that less of mutacin 1140 is 
made or the biosynthesis of mutacin 1140 by the bacterium is altered leading to the 
synthesis of less active products. Progressively longer truncations from residues Δ(-40 to 
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-33) and Δ(-40 to -28) were subsequently measured for bioactivity (Figure 2.2A and 
2.2B). The deletion mutants were reduced in bioactivity and the loss in bioactivity 
increased with the length of the deletion. The progressive loss in bioactivity with 
increasing size of deletion suggests that the length of the leader peptide is important for 
the biosynthesis of mutacin 1140. Mutacin 1140 was isolated from the Δ(-40 to -33) 
deletion mutant and its mass was 2265 Da, as predicted for a core peptide that has 
successfully undergone all dehydrations and decarboxylation (Table 2.1). There was no 
cyanylation of free thiols by CDAP, suggesting that all lanthionine rings were formed by 
the cyclase (Figure 2.3).  The substitution of six residues (-40 to -35) with histidines 
resulted in a statistically significant decrease in bioactivity, whereas, an insertion of six 
histidines between residues (-41 and -40) position resulted in no significant loss in 
bioactivity (Figure 2B). These results further emphasize the importance of the leader 
peptide's predicted secondary structure for bioactivity (Figure 2.1C). Secondary structure 
analysis using SOPMA (131) predicts that the N-terminal end of the leader peptide is an 
alpha helix, while the C-terminal end is a random coil (Figure 2.1C). The insertion of six 
histidines at the N-terminal end did not affect bioactivity because they presumably 
extend outside of a binding cleft, whereas the substitution of six histidines is within the 
leader peptide binding cleft of a PTM enzyme. The substitution of six histidines within 
this region is predicted by SOPMA to change the secondary structure to a random coil. 
Furthermore, the substitution of six histidines within this region would contribute to 
steric interference of binding. These results suggest that length of the first half of the 
leader peptide sequence, and possibly secondary structure, is more important for the 
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biosynthesis of mutacin 1140 than the actual amino acid sequence. The lack of sequence 
specificity for the leader peptide has also been reported in other lantibiotic systems (127, 
128, 132, 133). 
 
Table 2.1 MALDI-MS data for isolated mutacin 1140 products from S. mutans JH1140 
leader peptide mutants. 
Strain Mass (Da) 
S. mutans ATCC 55676 2264±1 
S. mutans Δ(-40-33) 2264±1 
S. mutans Δ(-40-28) N.D. 
S. mutans Δ(-40-24) N.D. 
S. mutans Δ(-40-37) 2264±1 
S. mutans Δ(-36-33) 2264±1 
S. mutans Δ(-32-28) 2264±1 
S. mutans Δ(-27-24) 2264±1 
S. mutans Δ(-23-20) N.D. 
S. mutans F(-27)A 2264±1 
S. mutans D(-26)A 2264±1 
S. mutans V(-25)A 2264±1 
S. mutans Q(-24)A 2264±1 
S. mutans Q(-24)insA 2264±1 
S. mutans E(-23)A 2264±1 
S. mutans E(-23)insA 2264±1 
S. mutans D(-22)A 2264±1 
S. mutans D(-22)insA N.D. 
S. mutans L(-21)A 2264±1 
S. mutans Δ(-21) 2264±1 
S. mutans L(-21)insA 2264±1 
S. mutans F(-20)A 2264±1 
S. mutans Δ(-20) 2264±1 
S. mutans Δ(-19) 2264±1 
S. mutans AALF 2264±1 
S. mutans EDED N.D. 
S. mutans N+6xhis  2264±1 
S. mutans N6xhis  2264±1 
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II.3.2 Mutations in the presumed FNLD box did not change activity 
 A comparison of leader peptide sequences of class I lantibiotics shows a 
conserved sequence within the first half of the leader peptide (Figure 2.1B). The 
F(N/D)LD box appears to be highly conserved among different lantibiotics (123, 128), 
but the predicted box sequence for mutacin 1140 is different compared to other 
lantibiotics. The box for mutacin 1140 was predicted to have the sequence FDVQ 
located at the (-27 to -24) region of the leader peptide (121). We individually substituted 
the amino acids FDVQ with alanine to determine their importance for bioactivity (Figure 
2A and 2C). Alanine substitutions did not exhibit any change in activity. Given the 
possibility that the effect of single point mutations could be masked by the presence of 
other amino acids within the sequence, we deleted the whole FDVQ box Δ(-27 to -24) 
from the leader peptide. The truncation also did not significantly reduce the bioactivity 
(Figure 2.2A and 2.2C). We isolated the lantibiotic from the culture and determined the 
mass. The mass of the mutant product in combination with its bioactivity suggested that 
the core peptide underwent all posttranslational modifications (Table 2.1). These 
observations are incompatible with what has been reported for other related lantibiotics. 
The substitution at the F(-18) position of nisin with an alanine was shown to reduce the 
bioactivity of this strain and the deletion of the F(N/D)LD box of nisin abolished 
production of the lantibiotic (127). We therefore searched downstream for a new box.  
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II.3.3 A novel four amino acid motif affects biosynthesis 
 Considering how the deletion of the predicted motif for mutacin 1140 did not 
affect production, additional deletion mutants were made to determine whether or not 
mutacin 1140 leader peptide has a unique “box motif” as has been characterized for nisin 
(126, 127, 134, 135). A deletion of four residues Δ(-23 to -20), positioned at the C-
terminal end of the predicted FDVQ box described above, resulted in a complete loss in 
bioactivity (Figure 2.2A and 2.2D). The box has an “EDLF” motif, which is a different 
primary sequence from other related lantibiotics. The loss of activity may be attributed 
to a loss in leader peptide affinity to the binding cleft of a PTM enzyme (126, 127, 134, 
135). However, the deletion of seventeen amino acids Δ(-40 to -24) resulted in nearly a 
complete loss in bioactivity, suggesting that this region is also capable of stabilizing an 
interaction within the binding cleft of a PTM enzyme. It would be unusual for the loss of 
just four amino acids Δ(-23 to -20) to result in a complete loss of activity, unless this 
region is important for anchoring the leader peptide at the correct position in the binding 
cleft or is essential for activating a functional conformation of one of the PTM enzymes. 
To test the importance of site specific amino acids that are necessary for binding, we 
substituted the EDLF box with alanine residues. Each of these alanine substitutions for 
E(-23)A, D(-22)A, and L(-21)A resulted in no loss in bioactivity (Figure 2.2A and 
2.2D). The alanine substitution for F(-20)A resulted in approximately a 24% reduction in 
bioactivity. An insertion of alanine residues in the region of the putative EDLF box was 
evaluated. The Q(-24)InsAla and E(-23)InsAla mutants did not disrupt the bioactivity. 
The D(-22)InsAla mutant resulted in an 88% reduction in activity, while the L(-
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21)InsAla did not result in any significant loss in bioactivity. Furthermore, a deletion at 
A(-19) position did not result in any reduction in bioactivity. Yet, a deletion at L(-21) or 
F(-20) resulted in approximately 25% reduction in activity. These mutations point to the 
importance of all four of the EDLF amino acids in the box.  For example, EDLF, 
EADLF, EDLAF, DLF, and EDF still have normal bioactivity, while EDLA, EDF, and 
EDALF had a significant reduction in bioactivity (Figure 2.2A and 2.2D). The relative 
position of the acidic amino acids (ED) from the hydrophobic amino acids (LF) appears 
to be important for bioactivity. Each of the acidic and hydrophobic amino acids is able to 
compensate for the substitution of a single alanine residue in the sequence without 
resulting in a large loss in bioactivity. To test the requirement of an acidic amino acid 
relative to the position of hydrophobic amino acid, the mutants AALF and EDED boxes 
were tested.  Each of these mutations resulted in a significant loss in bioactivity (Figure 
2.2A and 2.2D). AALF activity was reduced by ~25% and EDED activity was reduced 
by ~65%. These mutations further indicate the importance of the EDLF box, specifically 
the latter two amino acids in the motif. This motif could be a potential binding site for 
the dehydratase LanB. We were unable to isolate any product from the culture liquor in 
the EDED mutant strain, which suggests that the motif is important for biosynthesis. We 
were able to isolate the AALF mutant product which had a mass of 2265 Da. 
Furthermore, all of the substitution or insertion mutations within this region resulted in a 
product with a mass of 2265 Da, which is the mass of the product that has undergone all 
dehydration and decarboxylation modifications (Table 2.1). There was no cyanylation of 
free thiols by CDAP in the AALF, ∆L-20, ∆F-19, and F-19A box mutants, suggesting 
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that all lanthionine rings were formed by the cyclase (Figure 2.3). The reduction in 
bioactivity in connection with the isolation of only fully modified mutacin 1140 supports 
the notion that core peptide PTM enzyme modifications are important for transport.  
 
 
Figure52.2 Identification of structural elements within the mutacin 1140 leader peptide 
that are important for bioactivity. A) Covalent structure representation of the mutations 
made on the leader peptide. Bioactivity for leader peptide mutants were measured as the 
percent difference in the zone of inhibition between wild-type and the mutant strains. 
∆lanA strain was used as a negative control for bioactivity in all experiments. The 
change in activity was measured for: B)  N-terminal deletions of the leader peptide, C) 
mutations in the proposed FNLD-type box, D) mutation in a new box, For each 
mutation, the bioactivity has been compared to the activity of wild-type S. mutans 
JH1140 strain. Statistical method used was Student t-test and the asterisk signifies 
statistical significance (p<0.05). 
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Figure62.3 Cyanylation of free thiols by CDAP. A) MALDI-MS of peptide from  ∆(-40-
33) strain (A1) and CDAP treated peptide (A2); B) MALDI-MS of peptide from AALF 
strain (B1) and CDAP treated peptide (B2); C) MALDI-MS of peptide from ∆L-20 
strain (C1) and CDAP treated peptide (C2); D) MALDI-MS of peptide from ∆F-19 (D1) 
and CDAP treated peptide (D2); E) MALDI-MS of peptide from F-19A (E1) and CDAP 
treated peptide (E2); F) MALDI-MS of positive control peptide resact (F1) and CDAP 
treated peptide (F2). None of the isolated peptides from S. mutans mutant strains reacted 
with CDAP, while the positive control was cyanylated. 
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II.4. Discussion 
 Due to their unique structure, lack of resistance, and wide array of activity, 
lantibiotics have become a prime candidate for development of new therapeutics. 
Spontaneous resistance to lantibiotics like mutacin 1140 is highly unlikely given their 
mechanism of action (50-52, 136). Mutacin 1140, a lantibiotic produced by S. mutans 
JH1140, has been shown to be active against serious pathogens like MRSA (10). In this 
study, we investigated the role of structural regions within the leader peptide and core 
peptide for biosynthesis. Mutacin 1140 leader peptide sequence is different and longer 
than other lantibiotic leader peptides, while the core peptide sequence is similar to 
epidermin and nisin (Figure 1). A better understanding of the role of the leader peptide 
in the posttranslational modification of lantibiotics will allow us to advance the use of 
the PTM enzymes for the synthesis of mutacin 1140, novel lantibiotics, and therapeutic 
peptides.  
 In nisin, N-terminal mutagenesis studies upstream of the conserved FNLD box 
were tolerated by the PTM enzymes (137). We predicted that N-terminal truncations of 
the mutacin 1140 leader peptide would also be well tolerated and that the additional 
length may not be important for bioactivity. However, we did see a loss in activity with 
the increasing length of the deletion upstream of the newly identified box. Given that the 
small truncations of four and five amino acids over the same regions as covered by the 
larger deletion mutants did not reduce the bioactivity, site specific amino acids within 
this region of the leader peptide may not be important for recognition by the PTM 
enzymes. Presumably, hydrogen bonds are formed between the peptide backbone of the 
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N-terminal portion of the leader peptide and PTM enzyme. This type of interaction and 
not the interaction of the amino acid side chains of the leader peptide would account for 
the lack of sequence specificity. Other studies support a helical structure for the leader 
peptide in the binding cleft of the dehydratase of lacticin 481 and that secondary 
structure is important for activity (123, 138). These studies have shown that insertion of 
prolines, which would disrupt the helical structure, would reduce the bioactivity (123, 
138). Secondary structure prediction suggests that the N-terminal portion of mutacin 
1140 leader peptide is helical, while the C-terminal end is a random coil. The leader 
peptide sequence within the N-terminal region is presumably reserved to a subset of 
amino acids that will not disrupt the secondary structure or is reserved to amino acids 
that will not contribute to the steric hindrance of binding. Plat et al. have also reported a 
lack of sequence specificity within the nisin leader peptide (127).  
 Some models for the binding cleft suggest that both LanB and LanC have their 
own distinct regions for binding the leader peptide or that the interaction of LanB and 
LanC form the binding cleft for the leader peptide (128). There are two publications 
pertaining to the interaction of LanB and LanC that appear to have conflicting results. 
Mavaro et al. showed a 1:1 stoichiometry of binding of prenisin, dehydrated nisin, and 
fully modified nisin to LanB. The affinity of the prenisin with leader peptide was 
approximately 1 µM and the affinity of fully modified nisin with leader peptide was a 
log higher. The dehydrated form had a two-fold higher affinity to LanB than prenisin. 
This data would suggest that prenisin would prefer to associate with LanB and that 
cyclization may occur while being bound to LanB. Abts et al. reported the binding of 
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leader peptide to the cyclase LanC (126). The prenisin, dehydrated and fully modified 
nisin had similar binding affinities at approximately 2 µM. In this study, they showed 
that AALD and FNAA box mutations resulted in a complete loss of binding to LanC. 
However, synthesis of fully modified nisin was shown by Plat et al., while having 
similar mutations (127). This suggests that cyclase activity is occurring while leader 
peptide is bound to LanB and that LanC binding is not essential for cyclase activity. One 
would expect the formation of only a dehydrated nisin and not a biologically active 
peptide, if leader peptide binding to LanC was required. The study by Abts et al. does 
clearly show the requirement of the FNLD box for binding to LanC and seems to 
conflict with the study by Plat et al. (126, 127). In view of these results, it is possible that 
there are two functional leader peptide binding sites that are not competing for the leader 
peptide. Both sites may coordinate the binding of the leader peptide, so that the core 
peptide can access the catalytic sites of the PTM enzymes. Additional studies will need 
to be done to discern the importance of these two sites in nisin biosynthesis. Biologically 
active product was observed in the mutacin 1140 biosynthesis system in the EDLF box 
mutants AALF and EDED. The AALF mutant had a single product with the mass of a 
fully modified core peptide, while the peptide in the EDED mutant could not be isolated 
for mass characterization. The lack of CDAP derivatized products support complete 
lanthionine ring formation in the AALF mutant product. Mutations within mutacin 1140 
leader peptide box motif have similar characteristics to the mutants reported in the 
FNDL box in the nisin biosynthesis system.        
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 To date, the biosynthesis of only a handful of lantibiotics has been studied. 
Additional studies within other lantibiotic biosynthesis systems will promote our 
understanding of this dynamic process. One important goal to lantibiotic research is the 
application of the PTM enzymes toward the synthesis of novel therapeutic compounds. 
Surely, an expanded understanding of PTM enzymes in other lantibiotic systems will 
promote this endeavor. We believe that the EDLF box is a structurally important region 
that facilitates alignment of the leader peptide within the binding cleft of the dehydratase 
LanB, similar to the function of the FNLD box of nisin (121-123). However, the 
difference in leader peptide box motif and length suggest that the leader peptide binding 
site is evolutionarily unique to other class I lantibiotics. This brings to question, whether 
lantibiotics should be classified by structural elements within the leader peptide as has 
been previously reported (123) or should they be classified based on core peptide 
structure. The classification of lantibiotics by leader peptide does suggest evolutionary 
relatedness in their PTM systems and substrate specificities. Given the complexity of 
lanthipeptide biosynthesis, classification by leader peptide appears to be a more logical 
approach. Additional studies aimed at understanding substrate specificity of the PTM 
enzymes between lantibiotic systems may promote a better understanding of the 
evolutionary differences between the class I PTM enzymes. Our leader peptide 
mutagenesis study and the concomitant isolation of the mutagenic products provide a 
better understanding of mutacin 1140 leader peptide. Furthermore, the studies show that 
the leader peptide of mutacin 1140 has evolved novel structural elements that promote 
its interaction with its PTM enzymes and that these structural elements are unique when 
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compared to related class I lantibiotics. Further studies within mutacin 1140 biosynthetic 
pathway are underway to determine substrate specificity of mutacin 1140 biosynthesis 
system.    
 
II.5. Materials and methods 
II.5.1 Bacterial strains, plasmids and media 
 Bacterial strains and plasmids used in this study are listed in Table 2.2. The 
cloning strain Escherichia coli DH5α (Invitrogen, Carlsbad, CA) was cultured at 37°C 
on Luria-Bertani (LB) broth or agar. THyex broth (30g/L Todd Hewitt Broth, 3g/L yeast 
extract), THyex agar media (30g/L Todd Hewitt Broth, 3g/L yeast extract, 15g/L agar; 
Bacto, Sparks, MD) and Top agar media (30g/L Todd Hewitt Broth, 3g/L yeast extract, 
7.5g/L agar; Bacto, Sparks, MD) was used to culture S. mutans JH1140 ATCC 55676 
and Micrococcus luteus ATCC 10240 at 37°C.   
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Table 2.2 Strains and plasmids used in chapter II. All mutations were made in the 
wild-type strain JH1140. All the plasmids were isolated from E. coli DH5α cells. 
Strains used Plasmid 
Intermediate  
Description References 
S. mutans      
JH1140 
ATCC 55676 
 Wild-type bacteriocin 
producing strain 
Strain (124) 
lanA:IFDC2 pIFDC2 Gene replacement strain Plasmid 
(139) 
Δ(-40-33) pΔ(-40-33) 8 amino acid(AA) N-terminal 
truncation 
This study 
Δ(-40-28) pΔ(-40-28) 13 AA N-terminal truncation This study 
Δ(-40-24) pΔ(-40-24) 17 AA N-terminal truncation This study 
Δ(-40-37) pΔ(-40-37) 4 AA N-terminal truncation This study 
Δ(-36-33) pΔ(-36-33) Internal 4 AA truncation This study 
Δ(-32-28) pΔ(-32-28) Internal 4 AA truncation This study 
Δ(-27-24) pΔ(-27-24) Internal 4 AA truncation This study 
Δ(-23-20) pΔ(-23-20) Internal 4 AA truncation This study 
Δ(-7-2)* pΔ(-7-2) Internal 6 AA truncation This study 
F(-27)A pF(-27)A Single alanine substitution at 
presumed box 
This study 
D(-26)A pD(-26)A Single alanine substitution at 
presumed box 
This study 
V(-25)A pV(-25)A Single alanine substitution at 
presumed box 
This study 
Q(-24)A pQ(-24)A Single alanine substitution at 
presumed box 
This study 
Q(-24)InsAla p Q(-24)InsAla) Alanine insertion at EDLF 
motif 
This study 
E(-23)A pE(-23)A Single alanine substitution at 
EDLF motif 
This study 
E(-23)InsAla p E(-23)InsAla Alanine insertion at EDLF 
motif 
This study 
D(-22)A pD(-22)A Single alanine substitution at 
EDLF motif 
This study 
D(-22)InsAla p D(-22)InsAla Alanine insertion at EDLF 
motif 
This study 
L(-21)A pL(-21)A Single alanine substitution at 
EDLF motif 
This study 
Δ(-21) pΔ(-21) Single AA truncation at EDLF 
motif 
This study 
L(-21)InsAla p L(-21)InsAla Alanine insertion at EDLF 
motif 
This study 
F(-20)A pF(-20)A alanine substitution at EDLF This study 
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Table 2.2 Continued   
Strains used Plasmid 
Intermediate  
Description References 
Δ(-20) pΔ(-20) Single AA truncation at EDLF 
motif 
This study 
 Δ(-19) pΔ(-19) Single AA truncation at EDLF 
motif 
This study 
AALF pAALF Double alanine substitution at 
ED 
This study 
EDED pEDED ED substitution for LF This study 
N+6xHis* pN+6xhis 6xHis addition at N-terminus  This study 
N6xHis* pN6xhis 6xHis substitution at the N-
terminus 
This study 
M. luteus 
ATCC 10760 
 Indicator strain in the differed 
antagonism assay 
(40) 
E. coli DH5 α pCR®2.1-
TOPO® 
Intermediate cloning host Invitrogen® 
 
 
II.5.2 Mutagenesis leader peptide 
 The S. mutans genome database and lan gene cluster, GenBank/EMBL accession 
number (AF051560), was used to design primers for the mutagenesis and sequencing 
work. pIFDC2 (139) is an in-frame deletion (IFD) cassette vector, which uses a highly 
expressed constitutive promoter to drive the expression of a synthetic operon containing 
both a positive selection marker (ermAM) and a negative selection marker (-pheS*) 
(140). Approximately a 500 base pair (bp) amplification of DNA upstream of lanA 
(primers MutA-UpF and MutA-UpR-IDH) and ~500 bp amplification of DNA 
downstream of lanA (primers MutA-DnF-erm and MutA-DnR) were generated. These 
DNA fragments were attached to the 5’ and 3’ end of the IFDC2 cassette, respectively. 
Transformation of this PCR amplified product with S. mutans JH1140 ATCC 55676 
generated the S. mutans strain ΔlanA/IFDC2 (Table 2.2). S. mutans natural competence 
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pathway was used for transforming PCR and plasmid products. Natural competence can 
be activated using a competent stimulating peptide (CSP) (141). An overnight culture of 
S. mutans strain ΔlanA/IFDC2 was diluted to 0.1 OD600 and grown to 0.25 OD600 before 
the addition of 2 µL of 10 µg/mL CSP to 200 µL of bacterial suspension. After 30 
minutes of incubation, 1 µL of the PCR product of the IFDC2 cassette spanned by 
upstream and downstream DNA from the structural gene (lanA) was added to the cells. 
After 4-5 hours of incubation, 50 µL of solution was plated on THyex plates containing 
15 µg/mL of erythromycin. Colonies that grew in the presence of erythromycin were 
sequenced to confirm that the IFDC2 cassette replaced the lanA gene. This strain was 
used for subsequent transformations of plasmids containing leader peptide mutations. 
Leader peptide mutations were introduced into the lanA gene by 2-step PCR. The 
primers used to generate each leader peptide mutation are listed in Table 2.3. The 
mutations were then inserted into pCR®2.1-TOPO® vector according to the provided 
protocol. The transformants were sequenced by upstream and downstream primers 
approximately 300 bp from lanA using primers MutAsegF and MutAseqR. S. mutans 
ΔlanA/IFDC2 was transformed with the same protocol above with 1 µL of cloned 
pCR®2.1-TOPO® vector. The transformants of the leader peptide mutants were plated 
on THyex plates with 4mg/mL of chloro-phenylalanine. Colonies growing in the 
presence of chloro-phenylalanine represent the loss of the IFDC2 cassette and the 
insertion of the lanA with the expected mutation. Colonies from these plates were 
identically spotted on THyex and THyex with erythromycin to remove false positives 
from the screen.  Mutants were further confirmed by sequencing.  
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Table 2.3 Forward and reverse primers used in chapter II. 
Primer Sequence 
MutA-UpF-long GCTTCAATTCTTAAATCTAATTTGAATCAGCTTTTATAAA 
MutA-DnR-long TCGGATCACTATGTAGTAACTCAATGGGATCCATCG 
MutAseq-F GAGGCTAATGGTGGTATTATATTATTG 
MutAseq-R ACCAAGGACTTCTAATAATTGTG 
MutA-UpF GCTTCAATTCTTAAATCTAATTTGAATC 
MutA-UpR-IDH GAGTGTTATTGTTGCTCGGACGAGTACTGGATCGTC 
MutA-DnF-erm GGTATACTACTGACAGCTTCTTGTATAAAAGATTTAGATTGTGCC 
MutA-DnR TCGGATCACTATGTAACTCAA 
N-6xHis-F CATCATCATCATCATCATGAAGTCCTTGGTACTGAAAC 
N-6xHis-R ATGATGATGATGATGATGCATAATATCCTCCTTTTTCATGTG 
N+6xHisF GGAGGATATTATGCATCATCATCATCATCATTCAAACACACAATTATTAG 
N+6xHisR CTAATAATTGTGTGTTTGAATGATGATGATGATGATGCATAATATCCTCC 
Δ(-40-33)-F GAAAAAGGAGGATATTATGCTTGGTACTGAAACTTTT 
Δ(-40-33)-R AAAAGTTTCAGTACCAAGCATAATATCCTCCTTTTTC 
Δ(-40-28)-F GAAAAAGGAGGATATTATGTTTGATGTTCAAGAAGATC 
Δ(-40-28)-R GATCTTCTTGAACATCAAACATAATATCCTCCTTTTTC 
Δ(-40-24)-F GAAAAAGGAGGATATTATGGAAGATCTCTTTGCT 
Δ(-40-24)-R AGCAAAGAGATCTTCCATAATATCCTCCTTTTTC 
Δ(-40-37)-F GAAAAAGGAGGATATTATGTTATTAGAAGTCCTTGGT 
Δ(-40-37)-R ACCAAGGACTTCTAATAACATAATATCCTCCTTTTTC 
Δ(-36-33)-F TATTATGTCAAACACACAACTTGGTACTGAAACTTTT 
Δ(-36-33)-R AAAAGTTTCAGTACCAAGTTGTGTGTTTGACATAATA 
Δ(-32-28)-F CACACAATTATTAGAAGTCTTTGATGTTCAAGAAGATC 
Δ(-32-28)-R GATCTTCTTGAACATCAAAGACTTCTAATAATTGTGTG 
Δ(-27-24)-F CTTGGTACTGAAACTGAAGATCTCTTTGCT 
Δ(-27-24)-R AGCAAAGAGATCTTCAGTTTCAGTACCAAG 
Δ(-23-20)-F GAAACTTTTGATGTTCAAGCTTTTGATACAACAGTA 
Δ(-23-20)-R TACTGTTGTATCAAAAGCTTGAACATCAAAAGTTTC 
F(-27)A-F ACTGAAACTGCTGATGTTCAAG 
F(-27)A-R CTTGAACATCAGCAGTTTCAGT 
D(-26)A-F TGAAACTTTTGCTGTTCAAGAAG 
D(-26)A-R CTTCTTGAACAGCAAAAGTTTCA 
V(-25)A-F AACTTTTGATGCTCAAGAAGATC 
V(-25)A-R GATCTTCTTGAGCATCAAAAGTT 
Q(-24)A-F TTTGATGTTGCAGAAGATCTCT 
Q(-24)A-R AGAGATCTTCTGCAACATCAAA 
E(-23)A-F GTCCTTGGTACTGAAGCTTTTGATGTTCAAGAA 
E(-23)A-R TTCTTGAACATCAAAAGCTTCAGTACCAAGGAC 
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Table 2.3 Continued 
Primer Sequence 
D(-22)A-F TTTGATGTTCAAGAAGCTCTCTTTGCTTTTGAT 
D(-22)A-R ATCAAAAGCAAAGAGAGCTTCTTGAACATCAAA 
L(-21)A-F GATGTTCAAGAAGATGCCTTTGCTTTTGATACA 
L(-21)A-R TGTATCAAAAGCAAAGGCATCTTCTTGAACATC 
F(-20)A-F GTTCAAGAAGATCTCGCTGCTTTTGATACAACA 
F(-20)A-R TGTTGTATCAAAAGCAGCGAGATCTTCTTGAAC 
Q(-24)InsAla-F TTGATGTTCAAGCTGAAGATCTCT 
Q(-24)InsAla-R AGAGATCTTCAGCTTGAACATCAA 
E(-23)InsAla-F GTTCAAGAAGCAGATCTCTTTG 
E(-23)InsAla-R CAAAGAGATCTGCTTCTTGAAC 
D(-22)InsAla-F GATGTTCAAGAAGATGTCCTCTTTGCTTTTGAT 
D(-22)InsAla-R ATCAAAAGCAAAGAGGACATCTTCTTGAACATC 
L(-21)InsAla-F GAAGATCTCGCATTTGCTTTTG 
L(-21)InsAla-R CAAAAGCAAATGCGAGATCTTC 
Δ(-21)A-F TGTTGTATCAAAAGCGAGATCTTCTTGAAC 
Δ(-21)A-R GTTCAAGAAGATCTCGCTTTTGATACAACA 
Δ(-20)A-F TGTTGTATCAAAAGCGAGATCTTCTTGAAC 
Δ(-20)A-R GTTCAAGAAGATCTCGCTTTTGATACAACA 
Δ(-19)A-F TTCAAGAAGATCTCTTTTTTGATACAACAGATAC 
Δ(-19)A-R GTATCTGTTGTATCAAAAAAGAGATCTTCTTGAA 
AALF-F ACTTTTGATGTTCAAGCAGCTCTCTTTGCTTTTGAT 
AALF-R ATCAAAAGCAAAGAGAGCTGCTTGAACATCAAAAGT 
EDED-F GATGTTCAAGAAGATGAGGATGCTTTTGATACAACA 
EDED-R TGTTGTATCAAAAGCATCCTCATCTTCTTGAACATC 
 
 
II.5.3 Deferred antagonism assay 
 The deferred antagonism assay was performed as previously reported (40). S. 
mutans wild-type and mutant strains were grown overnight in liquid THyex culture. The 
next morning, the culture was diluted to 0.1 OD600 and allowed to grow to a mid-
logarithmic phase. The culture was then diluted to 0.05 OD600 before spotting 2 µl of the 
bacterial suspension on fresh pre-warmed THyex plates. A duplicate of triplicate spots 
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were tested for each strain with wild-type and ΔlanA serving as positive and negative 
controls, respectively. The plates were incubated 18 hours at 37°C in a candle jar. The 
next day the bacterial colonies were heat killed at 65°C for one and a half hours and then 
cooled to 37°C. M. luteus from a fresh overnight plate was used to inoculate pre-warmed 
THyex broth and grown at 37°C to a mid-logarithmic phase. The culture was then 
diluted to 0.2 OD600 and diluted 25-fold in pre-warmed (42°C) top agar. 5 mL of top 
agar containing the bacterial suspension was then poured onto each heat-killed plate and 
incubated overnight at 37°C. The area for each zone of inhibition was calculated and 
compared to wild-type zones of inhibition. The activity of the purified variants were 
determined using the same conditions for overlaying the indicator strain, in which 5 µL 
of the extracted variants were spotted on the pre-warmed THyex plates after being 
overlayed with M. luteus. Student t-test was the statistical method used determine 
significance (p<0.05). 
 
 
II.5.4 Isolation of mutacin 1140 leader peptide variants 
 Mutacin 1140 and variants of mutacin 1140 were isolated as previously reported 
(142). A modified THyex media was used as the fermentation media for inoculation. The 
media contained 30g/L Todd Hewitt, 3g/L yeast extract,  1 g/L NaH2PO4, 0.2 g/L 
Na2HPO4, 0.7 g/L MgSO4, 0.005 g/L FeSO4, 0.005 g/L MnSO4, and 0.3% agar. 500 mL 
of the semi-solid fermentation media was placed in a 1 L glass beaker and stab 
inoculated using an inoculating needle. The inoculum was placed at 37°C for 72 hours, 
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and immediately frozen at -80°C. The media was then thawed in a 55°C water bath for 1 
hour. The inoculum was then placed in 250 mL centrifuge bottles and centrifuged at 
20,000g for 30 minutes. The collected supernatant was pooled, mixed with chloroform at 
a 1:1 ratio, and shaken vigorously. The mixture was centrifuged again at 20,000g for 30 
minutes. The phase between the aqueous and chloroform layers was collected and 
allowed to dry overnight. The dried precipitate was resuspended in 35% acetonitrile and 
tested by deferred antagonism assay for activity. The crude extract was run on either a 
semi-prep C18 column (Agilent® ZORBAX, ODS, C18, 5µm, 4.6x250mm) or 
analytical column as previously reported (40). CDAP (1-cyano-4-
dimethylaminopyridinium tetrafluoroborate) and Tris [2- carboxyethyl] phosphine 
(TCEP) was used to determine whether the isolated products had any free thiols resulting 
from a lack of cyclase activity (143). We followed the procedure as has been previously 
reported by Kluskens et al. (134) with slight modification. We used 0.1 N hydrochloric 
acid to dissolve CDAP. As a positive control, we used an extended analog of the 
chemotactic peptide resact (LRGGGVCGPAGTVCGYGGG-NH2) (144). The purified 
products were confirmed by mass on a Shimadzu® MALDI-MS on both linear and 
reflectron modes. 
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CHAPTER III:                                                                                              
BIOSYNTHESIS AND TRANSPORT OF THE LANTIBIOTIC MUTACIN 1140 
PRODUCED BY STREPTOCOCCUS MUTANS
*
 
III.1. Synopsis 
Lantibiotics are ribosomally synthesized peptide antibiotics composed of an N-
terminal leader peptide that is cleaved to yield the active antibacterial peptide. There 
have been significant advancements in molecular tools that can be used in S. mutans that 
promote the study of lantibiotic biosynthesis in this bacterium. Herein, we further our 
understanding of leader peptide sequence and core peptide structural requirements for 
the biosynthesis and transport of the lantibiotic mutacin 1140. Our study on mutacin 
1140 biosynthesis shows a dedicated secondary cleavage site within the leader peptide, 
and the dependency of transport on core peptide PTMs. The secondary cleavage site on 
the leader peptide was found at the (-9) position, which occurs prior to the core peptide 
being transported out of the cell. The coordinated cleavage at the (-9) position was 
absent in the lanT deletion strain, suggesting that core peptide interaction with LanT 
transporter enables the uniform cleavage at the (-9) position. Following transport, the 
LanP protease was found to be tolerant to a wide variety of amino acid substitutions at 
the primary leader peptide cleavage site with the exception of arginine at the -1 position. 
Several leader and core peptide mutations produced core peptide variants that had 
                                                 
*
 Reprinted with permissions from Biosynthesis and transport of the lantibiotic mutacin 1140 produced by 
Streptococcus mutans by Jerome Escano, Byron Stauffer, Jacob Brennan, Monica Bullock, and James 
Smith. 2015. Journal of Bacteriology.19776. Copyright [2015] by American Society of Microbiology 
DOI: 10.1128/JB.02531-14 
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intermediate stages of PTM enzyme modifications supporting the concept that PTM 
enzyme modifications, secondary cleavage, and transport are occurring in a highly 
coordinated fashion.  
 
III.2. Introduction 
Lantibiotics are a class of ribosomally synthesized peptide antibiotics produced 
by Gram-positive bacteria such as Lactoccocus lactis and S. mutans (9, 151). 
Lantibiotics are characterized by the presence of posttranslational modifications, such as 
dehydrated residues and lanthionine rings. The modified residues Dha and Dhb are 
formed from dehydration of serines and threonines, respectively. The cyclization 
between a cysteine and either a Dha or Dhb forms a lanthionine or methyllanthionine 
ring, respectively. The biosynthetic gene cluster contains all the genes necessary to 
produce a lantibiotic. The lan operon for class I lantibiotics contains genes encoding for 
the lantibiotic peptide (lanA), the dehydratase (lanB) responsible for the dehydration of 
serine and threonine residues, the cyclase (lanC) responsible for the stereo-specific 
formation of the thioether linkages, and an ABC-like transporter (lanT) for the export of 
the modified peptide. The mutacin 1140 operon also contains an additional gene called 
lanD, which is essential for the C-terminal decarboxylation of the core peptide forming 
an AviCys residue (152). Lantibiotics contain a leader peptide sequence that is cleaved 
following posttranslational modifications by a dedicated protease called LanP (121, 
122). The substrate specificity of LanP varies among lantibiotics (123). In most 
lantibiotic systems, LanP is believed to be associated with the extracellular leaflet of the 
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membrane and cell wall (153). Therefore, cleavage does not occur until mutacin 1140 is 
transported out of the cell by LanT.  
The lantibiotic mutacin 1140, produced by S. mutans JH1140, has been shown to 
have a similar mechanism of action as another class I lantibiotic called nisin. Mutacin 
1140 and nisin have structurally similar rings A and B (Figure 3.1A) and both nisin and 
mutacin 1140 bind and abduct lipid II (24, 50-52, 136, 154). Mutacin 1140 has also been 
shown to be bactericidal to pathogenic bacteria such as MRSA with no significant 
development of resistance (10). Mutacin 1140 is one of a small group of peptides that is 
currently under preclinical development for the treatment of Gram-positive infections 
(155). Many studies have revealed that lantibiotics are structurally diverse and have 
activity differences to nisin.  For instance, mutacin 1140 is a class I lantibiotic like nisin.  
However, the core peptide of mutacin 1140 is 12 amino acids shorter than nisin. Mutacin 
1140 has the same ability to bind to lipid II, but it does not form bacterial membrane 
pores as nisin (24, 52). 
The leader peptide sequences of lantibiotics belonging to the same class 
generally share structural motifs related to their function. The mutacin 1140 leader 
peptide sequence is unique among class I lantibiotics in that it has little primary 
sequence similarities (Figure 3.1B). However, the leader peptide is similar in structure to 
mutacins produced by other S. mutans strains (124, 142, 156). Furthermore, there are 
considerable sequence differences in leader peptides among lantibiotics with similar core 
peptide structure. The leader sequence is between 19 to 48 amino acid residues long 
(123, 127). Due to the vast difference among leader sequences, studies have been 
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inconsistent with its actual function during lantibiotic biosynthesis. It has been suggested 
that the leader sequence is a signal for transport, inactivates the peptide to protect the 
producing strain, and provides recognition for PTM enzymes (117, 128, 157). There are 
conserved motifs found in some leader peptides, which provide a reasonable basis for 
the classification of lantibiotics. The common motif found in class I lantibiotics is the 
F(N/D)LD box (Figure 1B), which some studies show is important for the maturation of 
the core peptide antibiotic (126-128). Class II lantibiotics contain a GG or GA which is 
used as a cleavage site for the removal of the leader peptide from the core peptide and 
contain an upstream EV and/or EL conserved sequence motif (158, 159). Amino acid 
substitutions in the conserved regions within the leader peptide have shown that the 
composition of these common motif are important for the maturation of the core peptide, 
while a vast majority of the leader peptide does not have any amino acid sequence 
specificity (127, 128, 132, 160). Solution NMR studies have shown that the leader 
sequence lacks secondary structure (161), while the co-crystal structure of NisB in 
complex with the substrate peptide NisA shows an antiparallel β-strand (102).  It is 
likely that the leader peptide remains unstructured until it binds to the PTM enzymes. 
However, additional studies are needed to verify this assumption. Experimental studies 
suggest that the leader peptide is important for interacting with the dehydratase LanB, 
cyclase LanC, and transporter LanT (129, 130). However, these studies are challenged 
by the failure to distinguish between which of the proposed leader peptide functions that 
are affected by the changes in amino acid residues.  
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 Mutacin 1140 biosynthesis shares some important features with other lantibiotic 
systems, however, there are considerable differences in the biosynthesis between 
mutacin 1140 and nisin. In this study, we have identified a secondary cleavage site 
within the leader peptide. We have also shown relaxed substrate specificity for the LanP 
protease and that primary cleavage is not dependent on leader peptide sequence. 
Observations were made from several leader and core peptide mutations that supports 
the concept that the core peptide is not being shuttled between PTM enzymes and 
transporter by the leader peptide. Mutacin 1140 biosynthesis is a dynamic process in 
which PTM enzyme modifications and transport are occurring in a highly coordinated 
fashion, supporting the hypothesis that leader peptide binding at a single locus is 
sufficient for coordinating PTM enzyme modifications and transport.  
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Figure73.1 Structural elements commonly found in class I lantibiotics A) Covalent 
structures for nisin and mutacin 1140 with the lanthionine rings labeled from N- to C-
terminus. B) Leader sequence alignments of structurally related Class I lantibiotics; i.e. 
nisin produced by Lactococcus lactis, subtilin produced by Bacillus subtilis, epidermin 
produced by Staphylococcus epidermidis, gallidermin produced by Staphylococcus 
gallinarium, Pep5 produced by Staphylococcus epidermidis, epilancin K7 produced by 
Staphylococcus epidermidis, mutacin Ny266 produced by S. mutans Ny266, mutacin III 
produced by S. mutans UA787, mutacin 1140 produced by S. mutans JH1140, and for 
comparison a class II lantibiotic lacticin 481 produced by Lactococcus lactis (23, 142, 
145-150, 156). The F(N/D)LD box and C-terminal proline in class I lantibiotics is 
underlined and in bold print in the sequences. C) Secondary structure prediction using 
SOPMA for mutacin 1140 leader peptide; h (alpha helix), e (extended strand), c (random 
coil), t (beta turn). Alpha helical regions are underlined, while random coils are in bold 
in the leader peptide sequence. 
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III.3. Results 
III.3.1 Specificity of the MutP protease 
 We have previously reported that substitutions at the +1 position of the core 
peptide led to an increase in bioactivity or did not significantly reduce bioactivity (40). 
This suggests that the presence of F(+1) is not essential for cleavage by LanP. 
Alignments of the cleavage site of class I lantibiotics show a basic amino acid, such as 
arginine, at the (-1) position of the cleavage site and a conserved proline at (-2) or (-4) 
position (Figure 3.1B). Mutations were made to determine whether there is a recognition 
motif for LanP upstream of the cleavage site. Secondary structure analysis using 
SOPMA (131) predicts that the N-terminal end of the leader peptide (region (-32) to (-
39)) is an alpha helix, while the C-terminal end (region (-1) to (-8)) is a random coil 
(Figure 3.1C). Interestingly, the (-9) to (-20) region of mutacin 1140 leader peptide is 
primarily predicted to be an extended strand, which is in agreement with the secondary 
structure of nisin leader peptide in the co-crystal structure of NisA and NisB (102). 
Given the lack of predicted secondary structure at the C-terminal end of the leader 
peptide, LanP protease recognition would presumably be dependent on structural 
elements upstream or downstream of the primary cleavage site. First, alanine 
substitutions were made to determine the importance of the amino acids from the (-7 to -
1) position of the leader peptide (Figure 2A and 2B). The T(-2)A resulted in a slight 
reduction in activity, while the other alanine substitutions in residues (-7-3) had no 
statistical significant decrease in activity. The small change or lack of a statistically 
reproducible reduction in activity indicates that the region upstream of the cleavage site 
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does not have a strict motif for proteolytic activity. Interestingly, the substitution of the 
proline for an alanine at the (-4) position did not result in a decrease in bioactivity. The 
presence of a proline near the cleavage site is conserved among other class I lantibiotics 
and the lack of any change in bioactivity with the alanine substitution in this region 
suggests that the proline is not important for biosynthesis of mutacin 1140. We 
subsequently tested an alanine substitution at the R(-1) position. This mutation resulted 
in approximately a 90% loss in bioactivity (Figure 3.2B). The R(-1)A mutation signifies 
the importance of arginine at this position for LanP activity. The alanine substitutions (-
7-2) were also tested in the background of a lanP deletion strain to determine whether 
another protease can cleave the leader peptide. All the substitutions in the lanP deletion 
strain exhibited no activity against the indicator strain M. luteus, but activity was 
restored with the addition of trypsin to the top agar. Removal of the leader peptide using 
trypsin in a LanP deficient strain is possible given the presence of an Arg at the (-1) 
position of the leader peptide and the core peptide resistance to trypsin cleavage at the 
Lys2 and Arg13 position. Interestingly, the bioactivity was significantly larger in the 
∆lanP strain when trypsin was used to remove the leader peptide. HPLC of the extracted 
lantibiotic from the ∆lanP strain does yield at least a 2-fold increase in purified product 
(Figure 3.3). The histidine substitution of residues at the (-7-2) position resulted in an 
~85% reduction in activity, but did not completely remove all activity. This observation 
suggests that the LanP is still able to process the removal of the leader peptide 
containing six histidine substitutions, albeit, at a much lower efficiency. Furthermore, 
product could not be isolated from the culture broth, suggesting that biosynthesis or 
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transport of the product is drastically reduced with histidine substitutions of residues at 
the (-7-2) position. A substitution of histidine at the (-1) position of the leader peptide 
was evaluated. A histidine side chain has a pK = 6.0 and would predominantly be neutral 
at the physiological pH of the medium. We introduced this mutation to determine 
whether the positive charge within the (-1) position was essential for activity and figured 
this idea could be tested by changing the pH of the growth medium. Testing media with 
lower pH was not needed since there was no significant change in the bioactivity of the 
R(-1)H mutation in the medium with the neutral pH. However, we cannot rule out the 
possible need for a positive charge at the (-1) position, given that the lactic acid 
production by S. mutans could lower the pH around the bacterial colony enabling the 
histidine to be charged. This data does show that the LanP protease is tolerant to a wide 
variety of amino acid substitutions upstream of the primary leader peptide cleavage site 
and that R(-1) is not essential for the removal of the leader peptide.  
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Figure83.2 Identification of structural elements within the mutacin 1140 leader and core 
peptide that is important for bioactivity. A) Covalent structure representation of the 
mutations made on the leader peptide. Bioactivity for leader and core peptide mutants 
were measured as the percent difference in the zone of inhibition between wild-type and 
the mutant strains. ∆lanA strain was used as a negative control for bioactivity in all 
experiments. The change in activity was measured for: B) mutations near the LanP 
cleavage site, C) mutations within the newly discovered cleavage site, and D) mutations 
in the transporter lanT and core peptide regions responsible for ring formation. For each 
mutation, the bioactivity has been compared to the activity of wild-type S. mutans 
JH1140 strain.  All the activities are determined in the absence of trypsin in the top agar 
of the overlays. Statistical method used was Student t-test and the asterisk signifies 
statistical significance (p<0.05). 
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III.3.2 Discovery of an additional leader peptide cleavage site 
 MALDI-MS of purified products obtained from the culture broth of S. mutans 
∆lanP and R(-1)A strains contained single products with a mass of 3165 Da and 3079 
Da, respectively (Table 3.1). The peptide masses indicate the attachment of amino acids 
(-8 to -1) to the fully modified lantibiotic, instead of the whole 41 amino acid leader 
peptide as expected in the absence of LanP activity. This observation suggests that an 
additional cleavage site exists internally within the leader peptide between residues A(-
9) and S(-8). The absence of any inhibitory activity of these products also demonstrates 
that the truncated leader peptide does keep mutacin 1140 in an inactive structural state. It 
has been shown that biosynthesis of nisin in the absence of LanP produces partially 
cleaved leader peptide products (162, 163) with full length leader peptide being the main 
product (164).  Unlike nisin, only a single truncated leader peptide product is observed 
for mutacin 1140 leader peptide. To further understand the importance of the new 
cleavage site, point mutants were made at the new cleavage site in the S. mutans ∆lanP 
strain. This was done in order to prevent cleavage at the primary cleavage site R(-1). The 
S(-8) or A(-9) were substituted by either an alanine or phenylalanine (Figure 3.2A and 
3.2C). The switch to a smaller or bulkier side chain did not affect secondary cleavage 
activity nor did it affect the bioactivity of the mutant strains in the deferred antagonism 
assay when trypsin was added (Figure 3.2C). The masses were determined for the 
isolated mutant products and they still indicated the attachment of the 8 amino acid 
leader peptide (Table 3.1). Deletion of S(-8) yielded two products with a mass of 3063 
Da  and 2948 Da, which correspond to partial cleavage at N(-7) and D(-6) positions, 
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respectively. To further determine whether the cleavage is absolutely necessary, proline 
mutations were made at either S(-8) and N(-7) positions. Proline mutations will alter the 
position of neighboring amino acids by introducing a turn in the peptide structure. A 
proline mutation at S(-8) shifted the cleavage site to I(-11) or T(-13) as indicated by the 
mass of isolated products (Table 3.1). Interestingly, N(-7)P had major product with a 
cleavage site at I(-11) but also had multiple minor products with cleavage sites ranging 
from T(-13) to D(-6). P(-4)A only had a single product that had no shift in the cleavage 
site between A(-9) and S(-8) (Table 3.1). The structural region of the peptide at the P(-4) 
position is not important for the alignment of the peptide to be cleaved at the new 
secondary cleavage site. The structural region for aligning the peptide for cleavage 
presumably occurs upstream of the P(-4) position. We have previously shown that a 
serine engineered at the (+1) position does not undergo dehydration (40), suggesting that 
the distance from either the LanP or new cleavage site is important for a dehydration 
modification. We engineered a P(-4)A:F(1)S mutant to determine if the proline 
substitution would enable a dehydration at the (+1) position. The masses of the identified 
peptide products in the wild-type and lanP deletion strains were 2205 and 3078 Da, 
which corresponds to a product that is missing a dehydration. This suggests that the P(-
4)A substitution did not  promote a dehydration at the (+1) position and that the length 
from the (+1) position appears to be important for the dehydratase activity. Interestingly, 
the double mutant resulted in ~35% reduction in activity, whereas P(-4)A and F(1)S 
individual mutations resulted in no loss in activity. There was no cyanylation of free 
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thiols by CDAP in the P(-4)A:F(1)S mutant, suggesting that all lanthionine rings were 
formed by the cyclase. 
 Given that a deletion of S(-8) shifted the cleavage site downstream to N(-7) and 
D(-6) positions, we decided to investigate a larger deletion downstream of S(-8) 
position. The deletion mutant Δ(-7-2) was engineered in the wild-type and in the lanP 
deletion strains. The deferred antagonism assay for each of these strains had no 
bioactivity (Figure 3.2A, 3.2C, and 3.4A). Products were isolated from the culture liquor 
of these mutants and were characterized to have two predominant masses of 1936 and 
2508 Da. The 2508 Da product corresponds to the mutacin 1140 peptide that has 
undergone all of the posttranslational modifications with a short leader peptide of S(-2) 
and R(-1). Interestingly, the 2508 Da product is present in both the wild-type and lanP 
deletion strains. This suggests that LanP is not capable of processing the truncated (SR) 
leader peptide in this mutant strain. Trypsin was added to the extracted products to 
determine whether activity could be restored. The trypsin digested product did have 
inhibitory activity in our bioassay (Figure 3.4A) supporting the notion that all the 
posttranslational modifications are present within the 2508 Da mutacin 1140 product. 
The predominant mass of the mutant product is 1936 Da (Table 3.1 and Figure 3.4B and 
3.4C). This mass corresponds to a truncated mutacin 1140 peptide that has been cleaved 
between S(+3) and Trp(+4) position. Furthermore, the mass of the product corresponds 
to a loss of dehydration on a serine or threonine residue. We have previously shown that 
a serine engineered at the (+1) position or the P(-4)A:F(1)S strain does not undergo 
dehydration (40), suggesting that the distance from either the LanP or new cleavage site 
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is important for a dehydration modification. Therefore, a loss of a dehydration in the 
truncated core peptide product presumably occurs at the S(+5) position. 
The observation of the 2508 Da peptide corresponds to a fully modified core 
peptide that has two additional amino acids (SR-) from the leader peptide, while the 
1936 Da peptide corresponds to a variant that has been cleaved at S(+3) and is lacking a 
dehydrated Dha or Dhb residue. Given the observation of two distinct cleavage sites in 
the deletion mutant Δ(-7-2), there is a possibility that the 2508 Da peptide fragment has 
been cleaved at both the A(-3) and S(+3) positions, but is being held together by the 
thioether linkage in ring A. The lack of a single dehydration on the 1936 Da fragment 
enabled us to test this assumption by 2-mercaptoethanol (BME) derivitization of the two 
products. The lanthionine rings and the unsaturated amino acids Dha, Dhb, and the 
AviCys residues are susceptible to the addition of BME. The 2508 and 1936 Da peptides 
have seven and six modifiable positions, respectively. If there is no proteolytic cleavage 
between the S(+3) and Trp(+4) positions, derivitization of the 2508 and the 1936 Da 
peptide should both increase by ~78 Da for each addition of BME. If there is a 
proteolytic cleavage between the S(+3) and Trp(+4) position of the 2508 Da peptide, 
derivitization would provide a similar mass profile as the derivatized 1936 Da peptide. 
The latter scheme was observed following BME derivitization (Figure 3.4D). Given the 
absence of a dehydration and formation of a lanthionine ring in the 1936 Da peptide 
product, there would be approximately a 16 Da lower mass for each addition of BME to 
the 2508 Da peptide product. The mass difference of 16 Da is attributed to the lack of 
dehydration within the 1936 Da fragment and the loss of 2 Da from the formation of a 
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disulfide linkage between BME and the free thiol on the cysteine within the 1936 Da 
fragment. The addition of two to six BMEs were observed by MALDI-MS (Figure 
3.4D). 
Figure93.3 HPLC chromatograms of crude extracts obtained from modified THyex 
media inoculated with A) wild-type S. mutans JH1140 B) and S. mutans ∆lanP. There is 
more than a two-fold increase in isolated product from the S. mutans ∆lanP strain. 
67 
Figure103.4 Characterization of the leader peptide ∆(-7-2) mutant. A) Overlay assay 
using M. luteus as an indicator strain. From top left to bottom right: 5 µL spotted of 
purified mutacin 1140 (10 µg/mL) in acetonitrile:water (1:1); (negative control) 5 µL 
spotted of acetonitrile:water (1:1); deferred antagonism assay of S. mutans ∆(-7-2); 
deferred antagonism assay of S. mutans ∆lanP∆(-7-2); 5 µL spotted of trypsin digestion 
of product from  S. mutans ∆(-7-2); and 5 µL spotted of trypsin digestion of product 
from  S. mutans ∆lanP∆(-7-2). B) MALDI-MS data of product from  S. mutans ∆(-7-2). 
C) MALDI-MS data of product from  S. mutans ∆lanP∆(-7-2). D) MALDI-MS data of
the 2-mercaptoethanol (BME) derivitization of the isolated products from S. mutans ∆(-
7-2) strain. 
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Table43.1 MALDI-MS data for isolated products from S. mutans mutants in chapter III. 
Some mutant strains produced more than one product. The product masses are listed in 
the order of highest to lowest relative peak intensities. Some mutant products were not 
detectable (N.D.) and are listed in the table below. 
Strain Mass (Da) Leader sequence 
S. mutans ATCC 
55676 
2264.63±1 None 
S. mutans ΔlanP 3164.50±1 SNDDPDTR 
S. mutans A(-9)F 
ΔlanP 
3164.50±1 SNDDPDTR 
S. mutans S(-8)A 
ΔlanP 
3148.50±1 ANDDPDTR 
S. mutans S(-8)F 
ΔlanP 
3224.60±1 FNDDPDTR 
S. mutans Δ(-8) 
ΔlanP 
2963.32±1, 3077.42±1 DDPDTR, NDDPDTR 
S. mutans S(-8)P 
ΔlanP 
3457.90±1, 3660.12±1 IVAPNDDPDTR, 
TTIVAPNDDPDTR 
S. mutans N(-7)P 
ΔlanP 
3430.74±1, 3632.75±1, 
3317.66±1, 3218.59±1, 
3147.51±1, 2963.42±1 
IVASPDDPDTR, 
TTIVASPDDPDTR, 
VASPDDPDTR, 
ASPDDPDTR, 
SPDDPDTR, DDPDTR  
S. mutans N(-7)A 
ΔlanP 
3121.47±1 SADDPDTR 
S. mutans D(-6)A 
ΔlanP 
3120.49±1 SNADPDTR 
S. mutans D(-5)A 
ΔlanP 
3120.49±1 SNDAPDTR 
S. mutans P(-4)A 2264.63 
S. mutans P(-4)A 
ΔlanP 
3138.46±1 SNDDADTR 
S. mutans P(-
4)A:F(1)Ser 
2204.53±1 N.D. 
S. mutans P(-
4)A:F(1)Ser ΔlanP 
3078.36±1 SNDDADTR 
S. mutans D(-3)A 
ΔlanP 
3120.49±1 SNDDPATR 
S. mutans T(-2)A 
ΔlanP 
3134.47±1 SNDDPDAR 
S. mutans R(-1)A 3079.39±1 SNDDPDTA 
S. mutans R(-1)A 
ΔlanP 
3079.39±1 SNDDPDTA 
S. mutans R(-1)H 2245.58±1 N.D. 
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Table 3.1 Continued  
Strain  Mass (Da) Leader sequence 
S. mutans R(-1)H 
ΔlanP 
3145.45±1 SNDDPDTH 
S. mutans Δ(-7-2) 1936.23±1, 2507.76±1 None, SR 
S. mutans Δ(-7-2) 
ΔlanP 
1936.23±1, 2507.76±1 None, SR 
S. mutans C6xhis  N.D. N.D.  
S. mutans C(7)A 
(Ring A) 
1699.83±1, 2250.58±1, 
2232.57±1 
N.D. 
S. mutans C(11)A 
(Ring B) 
2250.58±1, 2278.57±1, 
2232.57±1 
N.D. 
S. mutans C(21)A 
(Ring C) 
2232.57±1 N.D. 
S. mutans S(19)A 
(Ring D) 
N.D. N.D.  
S. mutans 
C(7)A:C(11)A  
2218.52±1, 1943.17±1, 
3100.49±1 
SNDDPDTR 
S. mutans 
C(21)A:S(19)A 
N.D. N.D.  
S. mutans ΔlanT 2264.63±1 N.D. 
S. mutans ΔlanP and 
ΔlanT 
2849.23±1, 3165.50±1, 
3448.87±1, 2964.31±1, 
2894.24±1, 2637.02±1, 
2567.00±1 
DPDTR, SNDDPDTR, 
IVASNDDPDTR, 
DDPDTR, DPDTR, 
DTR, TR 
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III.3.3 Effects of lanthionine ring mutants on mutacin 1140 transport 
 Mutations were engineered to disrupt the formation of ring A, ring B, ring C, ring 
D, rings AB, and rings CD (Figure 3.2A and 3.2D). Alanine residues were substituted 
for the cysteines in rings AB and C. Given that the C-terminal cysteine is decarboxylated 
by LanD, an alanine was substituted for the serine in ring D. Three distinct peptides were 
isolated from the culture media for the ring A mutant (Table 3.1). A 2250 Da peptide 
corresponds to the core peptide that has not undergone a dehydration on one of its serine 
or threonine residues. The 2232 Da peptide corresponds to the core peptide that has 
undergone dehydration on all of its serine and threonine residues. A truncated core 
peptide with a mass of 1702 Da corresponds to the loss of FKSW from the N-terminal 
end. The major peptide mass indentified in the ring B mutant was 2250 Da followed by 
2232 Da, corresponding to the lack of a single dehydration within the core peptide and a 
core peptide that has undergone all dehydrations, respectively (Table 3.1). There was an 
additional peptide mass of 2278 Da. This corresponds to a core peptide that has 
undergone all dehydrations and lacks a C-terminal decarboxylation. Ring C mutant had 
only one peptide product with a mass of 2232 Da, which is the mass of the core peptide 
that has undergone all dehydrations (Table 3.1). There was no discernible product from 
the ring D mutant to obtain a mass (Figure 3.5). Formation of ring D appears to be 
absolutely necessary for transport. Ring A, ring B, and ring C mutants yielded 
approximately 60%, 90%, and 30% of the product compared to wild-type JH1140 
production based on peak volume measurements determined by HPLC chromatograms. 
The ring AB mutant yielded similar levels as the ring A mutant and the rings CD mutant 
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had no measurable product as ring D. Interestingly, the ring AB mutant had a minor 
product with a mass of 3100 Da that included the last 8 amino acids of the leader peptide 
(Table 3.1). The ring A, ring D, rings AB, and rings CD mutants had no inhibitory 
activity (Figure 2D). The ring B and ring C mutants had approximately 65% and 35% 
reduction in activity, respectively.  
 The bioactivity of the S. mutans ∆lanT strain was evaluated and it was found to 
be active in our deferred antagonism assay. The lack of the mutacin 1140 transporter 
only had approximately 20% reduction in activity. The isolated product from this strain 
had the predicted 2265 Da mass, suggesting that it had undergone all of the post 
translational modifications. These results show that there is an alternative transporter 
within S. mutans JH1140 that can transport mutacin 1140. Given the importance of the 
ring D region within the core peptide for transport (Figure 3.5), the alternative 
transporter in S. mutans JH1140 must also depend on the ring D region for transport. A 
double deletion strain of the lanP and lanT was generated to evaluate the nature of the 
leader peptide. Several peptide products were isolated that correspond to the core peptide 
containing a leader peptide of two to ten amino acids (Table 3.1). The variation in 
peptide length is similar to that observed with our proline mutations within the 
secondary cleavage site.  
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Figure113.5 Transport efficiencies of mutacin 1140 core peptide variants. Alanine 
substitutions were made to disrupt ring A (C(7)A), ring B (C(11)A), ring C (C(21)A), 
ring D (S(19)A), rings AB (C(7)A:C(11)A), and rings CD (C(21)A:S(19)A). Three 
independent extractions of each mutant strain were characterized by HPLC at 220 nm. 
Peak volumes of the variants of mutacin 1140 fractions were compared to wild-type 
strain JH1140 and are represented as percent of product relative to wild-type strain.  
Statistical method used was Student t-test and the asterisk signifies statistical 
significance (p<0.05). 
 
III.4. Discussion 
 In this study, we investigated the role of structural regions within the leader 
peptide and core peptide for biosynthesis. Mutacin 1140 leader peptide sequence is 
different and longer than other lantibiotics, while the core peptide sequence is similar to 
nisin, epidermin, and gallidermin. A better understanding of the biosynthesis of all 
lantibiotics will allow us to advance the use of the PTM enzymes for protein chemistry 
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applications and the design of novel peptide based therapeutics. We show that secondary 
cleavage, PTM enzyme modifications, and transport are highly coordinated activities.  
Terminal core peptide ring formations are essential for transport and the coordinated 
cleavage at the (-9) position is dependent upon the presence of the LanT transporter. 
LanP tolerates amino acid substitutions surrounding the primary cleavage site (-1).    
 A proline usually denotes a site of importance given that they confer breaks in 
secondary structure and cause turns in peptides or proteins. The P(-4)A mutant resulted 
in no significant loss in bioactivity. This observation suggests that there is no secondary 
structure within this region of the leader peptide and that this region is not important for 
PTM enzyme activity. Furthermore, there was no significant loss in bioactivity or 
notable interference with the activities of the LanB, LanC, LanD, or LanP PTM enzymes 
with the removal of the proline, P(-4)A, or the insertion of prolines, S(-8)P or N(-7)P. 
We only observe a statistically significant slight loss in activity with the T(-2)A 
substitution. However, bioactivity and mass of the isolated T(-2)A product show that it 
has undergone all dehydrations and decarboxylation. Secondary structure predictions 
suggest that the C-terminal end of the leader peptide is a random coil. Our mutational 
study also suggests that this region is functionally unstructured. We believe the 
unstructured region enables the interaction of the core peptide to the PTM enzyme active 
sites, while the upstream box motif of the leader peptide is tethered to a PTM enzyme 
binding site. This is supported by the co-crystal structure of NisA and NisB (102). The 
distinct leader peptide binding site and the flexibility of leader peptide residues (-1) to (-
8) along with the flexibility of the core region enables the core peptide to reach the 
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active site for glutamate elimination. Interestingly, following the disruption of Ring B 
formation in mutacin 1140, we saw a variant that contained a C-terminal carboxyl group. 
This variant suggests that the core peptide was not efficiently processed by the LanD 
decarboxylase. The inefficiency of decarboxylation activity supports the concept that 
PTM enzyme modifications are occurring under the dynamics of core peptide interaction 
to the PTM enzyme active sites guided by coordinated PTMs on the core peptide.        
 We saw at least a 2-fold increase in the amount of product isolated from the lanP 
deletion strain. One possible explanation for this increase in activity could be attributed 
to decrease in product association with the bacterial cell. The short leader core peptide 
fusion may not readily bind to the cell envelope and the lack of binding would facilitate 
our extraction from the media. Previous studies with mutacin 1140 suggests that a 
significant amount of the antibiotic is associated with the cell pellet (69).  Another 
possibility that we are exploring is whether the removal of the leader peptide from the 
core peptide has an inhibitory role in the production of mutacin 1140 or the leader 
peptide bound to core peptide is an activator for mutacin 1140 production. 
 The lack of specificity for both the upstream residues (-7-2) and the F(+1) 
position near the cleavage site indicates that the protease does not require the recognition 
of specific amino acid sequence near the cleavage site of the leader peptide. The 
specificity of cleavage by the LanP protease is unknown. It has been suggested that the 
specificity can come from structural elements within the core peptide, regions farther 
upstream of the core peptide, or the protease recognizes the tertiary structure of the 
truncated leader peptide and core peptide. The latter explanation is unlikely given the 
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substitution P(-4)A did not result in any loss in activity and that this region is predicted 
to be unstructured. Furthermore, the recognition of a region upstream of the S(-8) 
position is not likely given that the leader peptide is only eight amino acids given the 
presence of the secondary cleavage site. Core peptide recognition by NisP for the 
cleavage of the leader peptide has been suggested for nisin (117, 153, 165), and given 
the current results, core peptide structure is important for the specificity of mutacin 1140 
leader peptide cleavage by LanP. Additional studies will need to be done to determine 
whether LanP can recognize unmodified core peptide or whether PTM enzyme 
modifications are important for the recognition. The inability of the LanP protease to 
process the 2508 Da product's (SR) leader peptide when there was a cleavage at the 
S(+3) position of Ring A, suggests that the opening of Ring A prevented LanP cleavage. 
This is also supported by the observation in the lanT and lanP deletion strains, there was 
a (TR) leader peptide variant in the lanT and lanP deletion strain that was not present in 
the lanT deletion strain, suggesting that the short (TR) sequence was removed by LanP. 
Therefore, the short leader peptide appears to be recognized by MutP. Furthermore, the 
major product in the Ring A mutant was a truncated fragment (1699 Da) of the leader 
peptide. Additionally, a ring AB mutant had a minor product with 8 amino acids of the 
leader peptide (3100). This data suggests that an intact ring A is important for the 
specificity of cleavage by LanP or that the ring A mutant product is susceptible to 
proteolytic cleavage by another protease. It is possible for LanP to function in 
coordination with the transporter LanT and that this interaction coordinates protease 
 76 
 
specificity. However, we have shown that LanP is efficient at processing the removal of 
truncated leader peptides in the LanT deletion strain. 
  The (-7-2) deletion resulted in a cleavage within the core peptide S(+3) and a 
cleavage at the A(-3) position. This cleavage led to the formation of two peptide 
products with a mass of 1936 and 2508 Da. The presence of the 2508 Da fragment that 
has also been cleaved after the S(+3) position and held together by a thioether linkage, 
suggests that dehydration, cyclization, and secondary cleavage are functioning within a 
highly coordinated fashion. In our proposed model, the formation of the terminal 
lanthionine rings C and D stabilize an interaction with the transporter (LanT) and that 
this interaction coordinates the secondary cleavage at the (-9) position by an unidentified 
protease or proteolytic domain. There are two possible scenarios for the formation of the 
1936 and 2508 Da products. The first scenario would involve a highly mobile leader 
peptide moving back and forth from LanB to LanC enabling the coordination of 
dehydration and ring formation before coordinating the secondary cleavage that would 
yield the 1936 and 2508 Da products. A more simplified scenario would involve the 
binding of the leader peptide at a single position in which the core peptide can be acted 
upon by the PTM enzymes. This scenario would explain the formation of ring A, 
followed by the cleavage after S(+3) position and a subsequent lower frequency 
cleavage occurring after the (-3) position that would free the peptide for transport. The (-
7-2) deletion mutation presumably has a slower rate of dehydration at the S(+3) site, 
which prevents cyclase activity. Without the formation of ring A, the peptide is cleaved 
and transported yielding the 1936 Da fragment. If ring A forms, the peptide is still 
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cleaved at the (+3) position within the ring, but is not free to be transported until an 
additional cleavage occurs after the (-3) position. This data supports the view that 
secondary cleavage is an integral component to the biosynthesis of mutacin 1140 and 
that the PTM activity of dehydration, cyclization, secondary cleavage, and transport is a 
dynamic process acting on the core peptide in a highly coordinated fashion. 
 Secondary cleavage of the leader peptide was observed in the lanT and lanP 
deletion strain, albeit the cleavage appeared to be disordered and led to the formation of 
a number of peptide products. This suggests that the transporter is involved in 
coordinating the secondary cleavage site. The isolation of a 1936 Da product also 
suggests that transport of the core peptide is not directly dependent on the leader peptide. 
Given that cleavage at the secondary site is independent of LanT, it is logical to assume 
that the presence of the 1936 Da product is recognized and transported without an 
attached leader peptide.   
 The fact that cleavage still occurred regardless of the mutations made in the 
leader peptide, suggests that the new cleavage site on the leader peptide is an integral 
component within the biosynthetic pathway of mutacin 1140. The new cleavage site 
appears to rely more on the length of the leader sequence than the actual amino acid 
composition with the exception of the proline insertions. It is possible that cleavage aids 
in the release of the modified peptide from a PTM enzyme before transport or having a 
truncated leader peptide results in a more energy efficient approach for transporting the 
modified core peptide. Deletion of lanT resulted in the production of fully modified 
product, but in the background of the lanT and lanP deletion strain the ordered cleavage 
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between the A(-9) and S(-8) position was not observed. This is similar to the random 
cleavage observed in our A(-9)P and S(-8)P mutations. These mutations may interfere 
with the efficiency of transport of the modified product leaving it susceptible to cleavage 
by cytoplasmic proteases before being transported.  Furthermore, we observed a 
dependency on ring D formation for the isolation of any product from the mutacin 1140 
biosynthesis system. We believe that the interaction of the core peptide with the 
transporter coordinates the ordered cleavage at the A(-9) position and the absence of 
LanT leads to a random secondary cleavage within the leader peptide. S. mutans JH1140 
contains an alternative transporter that efficiently transports these products out of the 
cell. A lantibiotic transporter in a non lantibiotic producing strain of S. mutans GS-5 has 
been recently reported (166). In this study, the authors demonstrate that the transporter 
confers protection against two component lantibiotics similar to haloduracin and Smb. It 
is possible that lantibiotic transporters are more widespread in S. mutans given their 
environmental exposure to lantibiotic and non lantibiotic bacteriocins.   
 To date, the biosynthesis of only a handful of lantibiotics has been studied. Even 
though these studies have enriched our understanding of the PTM enzymes, we have 
barely scratched the surface of understanding how these enzymes coordinate their 
activities toward the synthesis of a fully functional lantibiotic without the production of a 
significant amount of side products. Studies within mutacin 1140 biosynthesis system 
and other lantibiotic biosynthesis systems will promote our understanding of this 
dynamic process. The structural variants isolated from our mutational study support a 
simplified model for mutacin 1140 biosynthesis; a model in which the leader peptide 
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binds to one locus that coordinates the core peptide PTMs. PTMs on the core peptide 
would occur under a dynamic process, dictated by distance of modifiable residues from 
PTM enzyme active sites and core peptide structural elements. The products isolated 
from our mutagenesis study do not support the current consensus within the field for 
class I lantibiotic biosynthesis, in which the leader peptide shuttles the core peptide to 
each PTM enzyme and transporter. For instance, the presence of products that were 
lacking dehydrations or C-terminal decarboxylation following disruption of ring A or 
ring B formation supports the coordinated activities of PTM enzymes following 
successive steps of core peptide modifications. Furthermore, a dedicated secondary 
cleavage site at the A(-9) position is present. Truncation mutations, ∆S(-8) or ∆(-7-2), 
resulted in a concomitant cleavage toward or within the core peptide, suggesting that the 
secondary cleavage is coordinated by the binding of the leader peptide upstream of the 
secondary cleavage site. Furthermore, the truncation of the C-terminal portion of the 
leader peptide also affected the rate of dehydration at S(+3) position or cyclase activity 
preventing ring A formation. These results further support the idea that the leader 
peptide is bound at one location and that the length of the C-terminal portion of the 
leader peptide is important for promoting an efficient interaction of the core peptide with 
the PTM enzymes.   
 The study provides a functional model for the biosynthesis of mutacin 1140 and 
other related lantibiotics. In this model, the PTM enzymes and transporter are 
functioning in a highly coordinated fashion, while the binding of the leader peptide to 
one of the PTM enzymes facilitates the core peptide's interaction with the PTM enzymes 
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and transporter. Following the secondary cleavage of the leader peptide at the A(-9) 
position facilitated by modified core peptide interaction with LanT transporter, the 
remaining portion of the leader peptide is released from the PTM enzyme and the core 
peptide with the truncated leader peptide is exported. Further studies within mutacin 
1140 biosynthetic pathway are underway to determine whether this model will satisfy all 
of our experimental observations.    
 
III.5. Materials and methods 
III.5.1 Bacterial strains, plasmids and media 
 Bacterial strains and plasmids used in this study are listed in Table 3.2. The 
cloning strain Escherichia coli DH5α (Invitrogen, Carlsbad, CA) was cultured at 37 °C 
on Luria-Bertani (LB) broth or agar. THyex broth (30 g/L Todd Hewitt Broth, 3 g/L 
yeast extract), THyex agar media (30 g/L Todd Hewitt Broth, 3 g/L yeast extract, 15 g/L 
agar; Bacto, Sparks, MD) and Top agar media (30 g/L Todd Hewitt Broth, 3 g/L yeast 
extract, 7.5 g/L agar; Bacto, Sparks, MD) was used to culture S. mutans JH1140 ATCC 
55676 and Micrococcus luteus ATCC 10240 at 37 °C.  S. mutans ATCC 55676 ∆lanP 
strain was obtained from Oragenics inc. 
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Table53.2 Strains and plasmids used in chapter III. Strains with an (*) indicate that 
mutations were made in both wild-type strain and ∆lanP strain. All other mutations were 
made in the wild-type strain JH1140. All the plasmids came from E. coli DH5α cells. 
Strains used Plasmid Intermediate  Description References 
S. mutans      
JH1140 ATCC 
55676 
 Wild-type bacteriocin producing 
strain 
Strain (124) 
lanA:IFDC2 pIFDC2 Gene replacement strain Plasmid (139) 
ΔlanP pIFDC2 
pΔlanP 
lanP deletion strain This study 
ΔlanT pIFDC2 
pΔlanT 
lanT deletion strain This study 
ΔlanP:ΔlanT pIFDC2 
pΔlanP 
pΔlanT 
lanP and lanT deletion strain This study 
A(-9)F* pA(-9)F Single Phe substitution at internal 
cleavage site 
This study 
S(-8)P* pS(-8)P Single Pro substitution at internal 
cleavage site 
This study 
S(-8)F* pS(-8)F Single Phe substitution at internal 
cleavage site 
This study 
Δ(-8)* pΔ(-8) Single truncation at internal cleavage 
site 
This study 
S(-8)A* pS(-8)A Single Ala substitution at internal 
cleavage site 
This study 
N(-7)P* pN(-7)P Single Pro substitution at internal 
cleavage site 
This study 
N(-7)A* pN(-7)A Single Ala substitution before 
cleavage site 
This study 
D(-6)A* pD(-6)A Single Ala substitution before 
cleavage site 
This study 
D(-5)A* pD(-5)A Single Ala substitution before 
cleavage site 
This study 
P(-4)A* pP(-4)A Single Ala substitution before 
cleavage site 
This study 
P(-4)A:F(1)S p P(-4)A:F(1)S Ala substitution before cleavage site 
and Ser substitution after cleavage 
site 
This study 
D(-3)A* pD(-3)A Single Ala substitution before 
cleavage site 
This study 
T(-2)A* pT(-2)A Single Ala substitution before 
cleavage site 
This study 
R(-1)A* pR(-1)A Single Ala substitution at primary 
cleavage site 
This study 
R(-1)H* pR(-1)H Single His substitution at primary 
cleavage site 
This study 
C6xHis* pC6xhis 6xHis substitution before primary 
cleavage site 
This study 
C(7)A pC(7)A Disruption of ring A formation This study 
C(11)A pC(11)A Disruption of ring B formation This study 
C(21)A  pC(21)A Disruption of ring C formation This study 
S(19)A pS(19)A Disruption of ring D formation This study 
 82 
 
Table 3.2 Continued   
Strains used Plasmid Intermediate  Description References 
C(7)A:C(11)A pC(7)A:C(11)A Disruption of ring A&B formation This study 
C(21)A:S(19)A pC(21)A:S(19)A Disruption of ring C&D formation This study 
M. luteus ATCC 
10760 
 Indicator strain in the differed 
antagonism assay 
Strain (40) 
E. coli DH5 α pCR®2.1-TOPO® Intermediate cloning host Invitrogen® 
 
 
III.5.2 Mutagenesis leader peptide 
 The S. mutans genome database and lan gene cluster, GenBank/EMBL accession 
number (AF051560), was used to design primers for the mutagenesis and sequencing 
work. pIFDC2 (139) is an in-frame deletion (IFD) cassette vector, which uses a highly 
expressed constitutive promoter to drive the expression of a synthetic operon containing 
both a positive selection marker (ermAM) and a negative selection marker (-pheS*) 
(140). Approximately a 500 base pair (bp) amplification of DNA upstream of lanA 
(primers MutA-UpF and MutA-UpR-IDH) and ~500 bp amplification of DNA 
downstream of lanA (primers MutA-DnF-erm and MutA-DnR) were generated. These 
DNA fragments were attached to the 5’ and 3’ end of the IFDC2 cassette, respectively. 
Transformation of this PCR amplified product with S. mutans JH1140 ATCC 55676 or 
S. mutans ∆lanP strain generated the S. mutans strain ΔlanA/IFDC2 and S. mutans strain 
ΔlanA/IFDC2 ∆lanP (Table 2). S. mutans natural competence pathway was used for 
transforming PCR and plasmid products. Natural competence can be activated using a 
competent stimulating peptide (CSP) (141). An overnight culture of either S. mutans 
strain ΔlanA/IFDC2 or S. mutans strain ΔlanA/IFDC2 lanP was diluted to 0.1 OD600 and 
grown to 0.25 OD600 before the addition of 2 µL of 10 µg/mL CSP to 200 µL of bacterial 
suspension. After 30 minutes of incubation, 1 µL of the PCR product of the IFDC2 
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cassette spanned by upstream and downstream DNA from the structural gene (lanA) was 
added to the cells. After 4-5 hours of incubation, 50 µL of solution was plated on THyex 
plates containing 15 µg/mL of erythromycin. Colonies that grew in the presence of 
erythromycin were sequenced to confirm that the IFDC2 cassette replaced the lanA gene. 
This strain was used for subsequent transformations of plasmids containing leader 
peptide mutations. Leader peptide mutations were introduced into the lanA gene by 2-
step PCR. The mutations were then inserted into pCR®2.1-TOPO® vector according to 
the provided protocol. The transformants were sequenced by upstream and downstream 
primers approximately 300 bp from lanA using primers MutAsegF and MutAseqR. S. 
mutans ΔlanA/IFDC2 was transformed with the same protocol above with 1 µL of 
cloned pCR®2.1-TOPO® vector. The transformants of the leader peptide mutants were 
plated on THyex plates with 4 mg/mL of chloro-phenylalanine. Colonies growing in the 
presence of chloro-phenylalanine represent the loss of the IFDC2 cassette and the 
insertion of the lanA with the expected mutation. Colonies from these plates were 
identically spotted on THyex and THyex with erythromycin to remove false positives 
from the screen.  Mutants were further confirmed by sequencing.  
 
III.5.3 Deferred antagonism assay 
 The deferred antagonism assay was performed as previously reported (40). S. 
mutans wild-type and mutant strains were grown overnight in liquid culture. The next 
morning, the culture was diluted to 0.1 OD600 and allowed to grow to a mid-logarithmic 
phase. The culture was then diluted to 0.05 OD600 before spotting 2 µl of the bacterial 
suspension on fresh pre-warmed THyex plates. A duplicate of triplicate spots were tested 
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for each strain with wild-type and ΔlanA serving as positive and negative controls, 
respectively. The plates were incubated 18 hours at 37 °C in a candle jar. The next day 
the bacterial colonies were heat killed at 65 °C for one and a half hours and then cooled 
to 37 °C. M. luteus from a fresh overnight plate was used to inoculate pre-warmed 
THyex broth and grown at 37 °C to a mid-logarithmic phase. The culture was then 
diluted to 0.2 OD600 and diluted 25-fold in pre-warmed (42 °C) top agar. 5 mL of top 
agar containing the bacterial suspension was then poured onto each heat-killed plate and 
incubated overnight at 37 °C. Trypsin was used to remove the leader peptide from the 
core peptide mutacin 1140 by adding it to the top agar at a concentration of 5 µg/ml. The 
area for each zone of inhibition was calculated and compared to wild-type zones of 
inhibition. Statistical method used was Student t-test to determine activity differences of 
each mutant strain with respect to wild-type activity. The activity of the purified variants 
were determined using the same conditions for overlaying the indicator strain, in which 
5 µL of the extracted variants were spotted on the pre-warmed THyex plates after being 
overlayed with M. luteus. 
 
III.5.4 Isolation of mutacin 1140 leader peptide variants 
 Mutacin 1140 and variants of mutacin 1140 were isolated as previously reported 
(142). A modified THyex media was used as the fermentation media for inoculation. The 
media contained 30 g/L Todd Hewitt, 3 g/L yeast extract,  1 g/L NaH2PO4, 0.2 g/L 
Na2HPO4, 0.7 g/L MgSO4, 0.005 g/L FeSO4, 0.005 g/L MnSO4, and 0.3% agar. 500 mL 
of the semi-solid fermentation media was placed in a 1 L glass beaker and stab 
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inoculated using an inoculating needle. The inoculum was placed at 37 °C for 72 hours, 
and immediately frozen at -80 °C. The media was then thawed in a 55 °C water bath for 
1 hour. The inoculum was then placed in 250 mL centrifuge bottles and centrifuged at 
20,000 g for 30 minutes. The collected supernatant was pooled, mixed with chloroform 
at a 1:1 ratio, and shaken vigorously. The mixture was centrifuged again at 20,000 g for 
30 minutes. The phase between the aqueous and chloroform layers was collected and 
allowed to dry overnight. The dried precipitate was resuspended in 35% acetonitrile and 
tested by deferred antagonism assay for activity. The crude extract was run on either a 
semi-prep C18 column (Agilent® ZORBAX, ODS, C18, 5µm, 4.6x250mm) or 
analytical column, as previously reported (40). 2-mercaptoethanol (BME) modifications 
of mutacin 1140 peptide variants was done as previously reported (24, 29). The lack of 
PTM cyclase activity would prevent lanthionine ring formation and result in the 
presence cysteine thiols that can be selectively labeled. CDAP (1-cyano-4-
dimethylaminopyridinium tetrafluoroborate) and Tris [2- carboxyethyl] phosphine 
(TCEP) was used to determine whether the isolated products had undergone all of the 
PTM cyclase modifications (143). We followed the procedure as has been previously 
reported by Kluskens et al (134) with slight modification. We used 0.1 N hydrochloric 
acid to dissolve CDAP. As a positive control, we used an extended analog of the 
chemotactic peptide resact (LRGGGVCGPAGTVCGYGGG-NH2) (144). The purified 
products were confirmed by mass on a Shimadzu® MALDI-MS on both linear and 
reflectron modes.  
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CHAPTER IV:                                                                                                     
EPIDERMIN CLASS LANTIBIOTICS, A NOVEL SCAFFOLD FOR LEAD 
ANTIBACTERIAL DISCOVERY 
IV.1. Synopsis 
 Mutacin 1140 belongs to the epidermin group of lantibiotics. A C-terminal 
AviCys residue is derived from the decarboxylation of a terminal cysteine that is 
involved in one of the lanthionine ring formations. Studies on mutacin 1140 have 
revealed new insights into the structural importance of the C-terminal AviCys residue. A 
C-terminal carboxyl analog of mutacin 1140 was engineered. Capping the C-terminal 
carboxyl group with a primary amine restores bioactivity and affords a novel opportunity 
to synthesize and test new analogs. For example, a C-terminal fluorescein labeled 
mutacin 1140 analog trap lipid II into a large lipid II lantibiotic complex, similar to what 
has been observed in vivo for the lantibiotic nisin. A C-terminal carboxyl analog of 
mutacin 1140 competitively inhibits the activity of native mutacin 1140 and nisin. The 
presence of a C-terminal carboxyl group prevents the formation of the large lipid II 
lantibiotic complexes, but does not prevent the binding of the lantibiotic to lipid II.  
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IV.2. Introduction 
 Lantibiotics are characterized by their PTMs. Dehydrations of serine and 
threonine residues into dehydroalanine and dehydrobutyrine residues, respectively, are a 
common modification found in lantibiotics. These dehydrated residues can be cyclized 
with cysteines to form thioether bridges, which are called lanthionines (121, 167). 
Lantibiotics can contain other posttranslational modifications, such as D-alanines in 
lacticin 3147, β-hydroxy aspartate in cinnamycin, 2-oxopropionyl in lactocin S, and an 
oxidized lanthionine in actagardine (28, 30, 82, 88). The epidermin group of lantibiotics 
and other lantibiotic peptides have an AviCys residue at the C-terminal end of the 
peptide (Figure 4.1A). This residue consists of a decarboxylated cysteine which forms a 
lanthionine ring. Several of these modifications have been shown to be important for 
lantibiotic activity, but the importance of the AviCys for activity remains poorly 
understood in the epidermin group of lantibiotics.   
 Mutacin 1140, produced by Streptococcus mutans JH1140 is a lantibiotic that has 
shown promise as a potential therapeutic (Figure 4l1B) (124, 168, 169). It has a broad 
spectrum of activity against Gram-positive bacteria (10). Moreover, mutacin 1140 has 
been shown to clear Staphylococcus aureus infections in rodent models with little 
associated toxicity (14). The producing bacterium of mutacin 1140 has been engineered 
into a therapy aimed at preventing dental caries (21). Biosynthetically, mutacin 1140 
belongs to the class I epidermin group of lantibiotics and is structurally related to 
epidermin and gallidermin (149, 170). The first two lanthionine rings, rings A and B, of 
the epidermin group are referred to as the lipid II binding domain. The lantibiotic nisin 
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shares structural homology to the lanthionine rings A&B. The latter half of the 
epidermin and nisin peptide is referred to as the lateral assembly domain, which 
presumably abducts lipid II into large lipid II/lantibiotic complexes (24, 51).  
 
 
Figure124.1 Structures of class I and class II lantibiotics containing AviCys residues. A) 
Structures of class I lantibiotics: mutacin 1140, epidermin, and nisin. Dehydrated 
residues are either Dha or Dhb. The lipid II binding domain of class I lantibiotics consist 
of the first two lanthionine rings A and B, while the lateral assembly domain consist of 
the terminal rings. B) Structure of the class II lantibiotic, mersacidin, which contains an 
AviCys. Residues involved in AviCys formation are labeled in red for both classes. 
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Decarboxylation of a C-terminal cysteine to form an AviCys residue occurs in 
several metabolites (171). AviCys is present in the class II lantibiotics mersacidin and 
microbisporicin (171, 172). It is also found in non-lantibiotics, such as cypemycin. 
Cypemycin contains many of the lantibiotic PTM modifications, but does not form 
lanthionine rings (173). Lastly, the AviCys residue, also, has been found in the 
nonribosomal peptide synthetases (NRPS) produced metabolite thiovideramide. The 
mechanism of AviCys formation for the NRPS peptide maybe different due the nature of 
its biosynthesis (174). In lantibiotics, decarboxylation is performed by the flavoprotein 
LanD. This decarboxylase has been shown to be specific for C-terminal cysteines. 
Furthermore, LanD could not decarboxylate an ethyl-thioether mimic, suggesting 
decarboxylation occurs before ring D formation (175). Crystal structures for both EpiD, 
the decarboxylase for epidermin, and MrsD, the decarboxylase for mersacidin, indicates 
that the enzyme forms a homo-dodecamer (137, 176). Studies on the mechanism of 
activity suggest that decarboxylation produces an ene-thiol intermediate that promotes 
terminal ring formation (177). There have been no reports of an isolated carboxylated 
analog of an AviCys containing lantibiotic, even in an EpiD deletion mutant of 
epidermin biosynthesis (178). A free carboxyl group analog of the epidermin group of 
lantibiotics would promote studies aimed at understanding the functional basis for 
AviCys residues within the lantibiotic.  
 Chemical modification of lantibiotics offers a novel avenue for the development 
of new types of therapeutics (179).  HOAt/EDC coupling has been achieved for 
lantibiotics that contain a C-terminal carboxyl group. NVB302, an analog of actagardine 
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which has undergone phase 1 clinical trials, has a diaminoheptane tail attached to the C-
terminus of the lantibiotic (113). Additionally, lantibiotics can be produced through 
solid-phase peptide synthesis using orthogonally protected lanthionine rings (179, 180). 
The lack of a C-terminal carboxyl group complicates the further development of the 
epidermin group of lantibiotics using these methods. We engineered a C-terminal 
carboxyl analog of mutacin 1140 that promoted studies toward understanding the 
functional importance of the AviCys residue in the epidermin group of lantibiotics.  
 
IV.3. Results 
IV.3.1 Engineering the production of a c-terminal carboxyl analog of an epidermin 
group lantibiotic 
 A C-terminal carboxyl analog for the epidermin group of lantibiotics has not 
\been characterized. Several structural analogs of mutacin 1140 were identified when the 
formation of ring B was disrupted by a C(11)A mutation. The mutation interfered with 
the formation of the PTMs normally found within mutacin 1140 and one of the peptide 
analogs had not undergone a C-terminal decarboxylation (32). This observation 
supported the basis for engineering S. mutans JH1140 to produce a mutacin 1140 C-
terminal carboxyl analog (mu1140-COOH). Deletion or insertional mutagenesis of mutD 
was done using the IFDC2 gene replacement system (Figure 4.2A) (139). A deferred 
antagonism assay, using the indicator strain Micrococcus luteus ATCC 10240, was 
performed on the S. mutans insertional IFDC2:mutD and S. mutans ΔmutD mutant 
strains. Neither mutant strains produced clear zones of inhibition (Figure 4.2B), 
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suggesting that the mutants did not produce a product or that the product was inactive. 
The culture broth of each mutant was extracted using the same extraction method for 
wild-type mutacin 1140. These extracts were run on an HPLC, as previously described 
(40), there was no observable product for the ∆mutD strain. The ribosomal binding site 
(RBS) for mutP protease is within the 3' end of the mutD gene. Careful consideration 
was made to leave the RBS in the deletion strain. However, there may be other elements 
important for the synthesis of downstream products that are not readily apparent. 
Nevertheless, a single HPLC peak for IFDC2:mutD strain was isolated and further 
characterized (Figure 4.2C). The IFDC2 cassette is under the control of a constitutive 
lactose dehydrogenase (ldh) promoter and it is likely that this promoter facilitates the 
expression of the downstream genes. The product purified from this mutant was 
analyzed by MALDI-MS and had a mass of 2310 Da. This mass corresponded to the 
expected mass of a C-terminal carboxyl analog of mutacin 1140. A MIC assay 
performed using mu1140-COOH analog against M. luteus revealed a 256-fold reduction 
in activity compared to wild type mutacin 1140. Furthermore, the activity of mu1140-
COOH against Streptococcus pneumoniae ATCC 27336 was greater than 64 ug / mL, 
which is more than a 128-fold reduction in activity (Table 4.1). The loss in activity in the 
MIC assays further corroborates the lack of activity seen in the deferred antagonism 
assays. The reason for the absence of activity may be attributed to the presence of the 
carboxyl group or it could indicate that the presence of the carboxyl group has disrupted 
the occurrence of other PTMs found in mutacin 1140.  
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Figure134.2 Deletion of mutD in S. mutans JH1140 A) Scheme for the deletion of mutD 
by IFDC2 gene replacement. B) Deferred antagonism assay against M. luteus ATCC 
10240 shows no zone of inhibition for either S mutans IFDC2:mutD or S. mutans 
ΔmutD.  S. mutans JH1140 and S. mutans ΔmutA were used as a positive and negative 
controls, respectively. C) Purification of S mutans IFDC2:mutD extracts (green) show a 
single peak, while there was no observable peak for S. mutans ΔmutA  and ΔmutD. 
 
 93 
 
Table64.1 Mass and activity of chemically modified analogs of mutacin 1140 against 
select bacteria. 
Mutacin 114O analog Expected 
Mass (Da) 
Observed 
Mass (Da) 
MIC 
(µg/mL) M. 
luteus 
MIC (µg/mL) 
S. pneumoniae 
Mutacin 1140 2264.63 2264.63 0.125 0.5 
Mu1140 - COOH 2310.65 2310.63 32 >64 
Mutacin 1140 – 
methylamine 
2325.72 2325.42 0.125 0.5 
Mutacin 1140 – 
diaminoheptane 
2422.88 2421.97 0.25 2 
Mutacin 1140 – 4-
chlorobenzylamine 
2436.25 2435.80 1 8 
Mutacin 1140 -  
3,4-
dichlorobenzylamine 
2470.69 2468.26 4 8 
 
 MALDI-MS analysis can determine dehydrations due to an observable change in 
mass. It cannot determine the formation of a lanthionine ring after dehydration, since the 
PTM does not result in a change in mass of the peptide. Therefore, the formation of the 
lanthionine rings needed to be assessed by another method. A rapid and straight forward 
Edman sequencing method was developed by our group in order to distinguish between 
dehydrated residues and dehydrated residues involved in lanthionine ring formation (29). 
Dehydrated residues are first hydrated by sodium borohydride before lanthionine ring 
derivatization by an organothiol compound. This method determines where the 
lanthionine rings are formed and the location of all the dehydrated residues, thus, 
elucidating the covalent structure of the lantibiotic peptide. Sodium borohydride 
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reduction of Dha and Dhb residues results in the formation of alanine and 2-
aminobutyric acid, respectively.  Subsequent ethanethiol derivatization opens the 
lanthionine rings, which form either thioethyl cysteines (S-EC) or β-methylthioethyl 
cysteines (β-M-S-EC). The presence of an S-EC or BM-S-EC residue at the amino acid 
positions 3, 8, 16, and 19 indicate that the free thiols of upstream cysteines had reacted 
with their downstream dehydrated residues to form a lanthionine ring. As predicted, 
alanine and 2-aminobutyric acid were observed in positions 5 and 14, respectively 
(Figure 4.3). These correspond to the reduction of the Dha5 and Dhb14 residues.  S-EC 
or BM-S-EC residues were observed in the expected amino acid positions 3, 8, 16, and 
19 (Figure 4.3), confirming that they were involved in lanthionine ring formations. The 
observed data suggested that the loss of activity was not due to disruptions to the other 
PTM’s, and that the observed loss in bioactivity of the mu1140-COOH analog was due 
to the presence of a C-terminal carboxyl group. 
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Figure144.3 Edman sequencing of mutacin 1140-COOH. A) After double labeling with 
sodium borohydride and ethanethiol, a thio-ethyl cysteine (S-EC) or beta-methyl thio-
ethyl cysteine (BM-S-EC) is expected at sites of lanthionine ring formation in the Edman 
sequence compared to mutacin 1140. Blue circles indicate residues expected to form 
lanthionine rings, and green circles indicate sites of dehydration. B) Select Edman 
sequence spectras for the modified residues indicate full modification of mu1140-
COOH. The red X or black circles indicate residues with no signal acquired. 
 
IV.3.2 Restoration of bioactivity of the c-terminal carboxyl analog of an epidermin 
group lantibiotic 
 Removal of the carboxyl group by MutD was first attempted to confirm that the 
presence of the C-terminal carboxyl group is responsible for the loss in bioactivity. A C-
terminal histidine tag of MutD was constructed and overexpressed in Escherichia coli. 
The purified product on an SDS-PAGE gel had the expected monomer size of 25 kDa, 
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but subsequent purification through FPLC showed a product that was approximately 200 
kDa. A 200 kDa mass is consistent with the formation of a homododecamer, as was 
previously reported for the epidermin decarboxylase EpiD (176). To determine if the 
enzyme was active, a reference peptide SFNSYTC, was incubated with MutD for one 
hour. A mass of 797.67 Da determined by MALDI-MS was observed for the reference 
peptide compared to 843.69 Da for the unreacted peptide, indicating that the 
decarboxylase was active (Table 4.2). The mu1140-COOH analog was incubated with 
MutD for one or ten hours and showed no indication of a mass change by MALDI-MS 
(Table 4.2). These results suggested that MutD was not capable of decarboxylating the 
mu1140-COOH analog. 
 
Table74.2 Mass of mu1140-COOH and control peptide after in vitro decarboxylation 
with MutD. 
Substrate Mass before 
reaction (Da) 
Expected mass  
(Da) 
Observed mass  
(Da) 
SFNSYTC (1hr) 843.69 797.67 797.67 
Mu1140-COOH 
(1hr) 
2310.37 2265.37 2310.63 
Mu1140-COOH 
(10hr) 
2310.37 2265.37 2310.63 
 
 Given that MutD could not remove the C-terminal carboxyl group, the C-
terminal carboxyl group was chemically modified and tested to determine whether C-
terminal substitutions could restore the bioactivity. EDC coupling of primary amines 
was used to cap the C-terminal carboxyl group (Figure 4.4). None of the primary amines, 
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tested on their own, had any activity against the indicator strains used in this study. EDC 
coupling with methylamine, the smallest primary amine, was first attempted. The 
conjugation with methylamine yielded a product with a mass of 2321 Da, indicating that 
the reaction occurred (Table 4.1). Based on the HPLC spectra, the reaction did not yield 
any other side products and the methylamine product was greater than 95% of the 
material (data not shown). There was a small amount of unreacted mu1140-COOH 
analog eluting before the conjugated methylamine product. The methylamine conjugated 
mutacin 1140 analog had an MIC of 0.125 µg/mL against M. luteus, and 0.5 µg/mL MIC 
against S. pneumoniae. These values were the same as the MIC values for native 
mutacin 1140. These results show that capping mu1140-COOH with a small primary 
amine restores activity to wild type levels. This data also supports the notion that the 
presence of a C-terminal carboxyl group is responsible for the reduction in mu1140 
activity. We subsequently conjugated diaminoheptane with mu1140-COOH. The activity 
of the diaminoheptane conjugate was 0.5 µg/mL against M. luteus and 2.0 µg/mL against 
S. pneumoniae. The addition of two different chlorinated aromatic rings with mu1140-
COOH was also tested. The activity of 4-chlorobenzylamine conjugate was 1.0 µg/mL 
against M. luteus and 2.0 µg/mL against S. pneumoniae. For the 3,4-
dichlorobenzylamine conjugate, the activity was 1.0 µg/mL and 8.0 µg/mL against M. 
luteus and S. pneumoniae, respectively. All the conjugates restored the activity of the 
mu1140-COOH analog, supporting the synthesis of a library of analogs that can be 
screened for novel applications.  
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Figure154.4 Scheme for chemical modification of mu1140-COOH. Mu1140-COOH 
analog was coupled to various primary amines using HOAt/EDC coupling. Primary 
amines were chosen based on size and differences in physiochemical properties. 
Reaction conditions were constant for each substrate, and yields were greater than 80% 
for each substrate. 
 
Fluorescently-labeled nisin, containing a C-terminal conjugate of fluorescein, 
forms lipid II patches on the surface Bacillus subtilis cells (51). The binding of lipid II 
by an epidermin group of lantibiotics has been shown in various in vitro assays(52), but 
the bioactivity has never been visualized in vivo. This is due to the lack of amenable 
attachment site for a fluorophore. The free carboxyl group on the mu1140-COOH analog 
is one such site. Therefore, a C-terminal fluorescein conjugate of mutacin 1140 was 
evaluated. The product had the expected mass of 2623 Da and was shown to have 
inhibitory activity on a deferred antagonism assay. For comparison, a C-terminal 
fluorescein conjugate of nisin was also made as previously described (51). As shown by 
Hasper et al, B. subtilis cells incubated with fluorescein labeled nisin showed large green 
patches on the cell surface (Figure 4.5). The green patches have been attributed to lipid 
II abduction and sequestration by nisin from its normal physiological location. Similar to 
what was observed for nisin, the C-terminal fluorescein-labeled mutacin 1140 produced 
patterns of fluorescent patches (Figure 4.5). This data supports in vitro data from the 
epidermin group of lantibiotics for lipid II binding and sequestration and also 
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demonstrates that this group of lantibiotics does sequester lipid II from its normal 
physiological location for cell wall synthesis.  
 
 
Figure164.5 In vivo localization of mutacin 1140. B. subtilis PY79 cells were incubated 
with various fluorescein conjugated lantibiotics. A) A no antibiotic sample was used as a 
negative control. B) Fluorescein conjugated nisin binds and abducts lipid II to form 
patches as expected. C) Fluorescein conjugated mutacin 1140 has a similar localization 
pattern as nisin. Images were taken using a confocal Olympus microscope using a 100x 
objective, or a 40x objective for the control. 
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IV.3.3 Further elaboration for the loss of activity for the c-terminal carboxyl analog 
 With the loss of activity associated with a free carboxyl group in mu1140-
COOH, we sought to determine the basis for the loss in activity. The mechanism of 
action for class I lantibiotics has already been determined to be due to lipid II binding 
(33, 181, 182). In particular, rings A and B are believed to form a cage-like structure 
around the pyrophosphate moiety of lipid II (154). The latter half of the peptide is 
predicted to enhance binding and recruit other lipid II-lantibiotic molecules into a large 
lipid II-lantibiotic complex (51). Given that lipid II binding is done by the N-terminal 
rings A and B, it is likely that the loss of activity is due to a loss in the lateral assembly 
function of the latter half of the peptide. To test for this assumption, we performed a 
series of experiments to determine whether the mu1140-COOH would bind to lipid II or 
competitively block lipid II binding of nisin in vivo. A TLC plate assay was used to 
determine if mu1140-COOH could bind to lipid II, as has been previously reported for 
gallidermin (183). If lipid II migration on the TLC plate is impeded by binding to 
mutacin 1140 or mu1140-COOH, an iodine stained spot is observed at the origin. No 
stain was visible for mutacin 1140, mu1140-COOH, and lipid II, when the compounds 
were spotted alone. However, a stained spot appeared at the origin when mutacin 1140 
or mu1140-COOH were spotted with lipid II (Figure 4.6). The mu1140-COOH analog 
mixed with lipid II showed a faint stain compared to lipid II mixed with wild-type 
mutacin 1140. The faint staining may be attributed to a weaker association of mu1140-
COOH with lipid II than mutacin 1140. If mu1140-COOH is capable of binding to lipid 
II, but does not inhibit cell growth, it may provide resistance to a bacterium against 
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mutacin 1140 or nisin. A competition MIC for mutacin 1140 and nisin was then 
performed against B. subtilis and M. luteus that were pretreated with mu1140-COOH. B. 
subtilis and M. luteus were pretreated with mu1140-COOH at 0.25µg/mL and 
0.125µg/mL, respectively, before adding mutacin 1140. Mu1140-COOH competitively 
inhibited the activity of mutacin 1140 against B. subtilis and M. luteus by 4-fold (MIC 
1.0 µg/mL and 0.5µg/mL, respectively) (Table 4.3). When pretreated with 0.5 µg/mL of 
mu1140-COOH, the activity of nisin was competitively inhibited against B. subtilis and 
M. luteus by 4-fold and 2-fold, respectively (MIC 2.0 µg/mL and 1.0 µg/mL). To further 
clarify a mechanism of action for the loss of activity in the MIC competition assay, 
confocal microscopy was used to observe nisin binding as previously described (34). If 
mu1140-COOH is still binding to lipid II in vivo, it should competitively inhibit the 
binding of fluorescein labeled nisin (Figure 4.7). When the bacteria were pretreated with 
wild-type mutacin 1140 or mu1140-COOH, no typical in vivo fluorescence pattern was 
observed for the fluorescein labeled nisin (Figure 4.7). However, there was some 
association of fluorescein labeled nisin with the bacteria, but nothing remotely similar to 
fluorescein labeled nisin on its own. This may be due to the weaker association of 
mu1140-COOH to lipid II, which further corroborates the weak association with lipid II 
observed in the TLC assay. These results suggest that the loss in activity is not due to its 
inability to bind to the lipid II target, but due to its inability to form the large lantibiotic 
lipid II complexes.  
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Figure174.6 In vitro lipid II binding assay. TLC plate assay of mutacin 1140 or 
mu1140-COOH mixed with lipid II. Binding of lipid II will keep lipid II at the origin. 
Lipid II or mu1140-COOH by itself was used as a negative control showing no staining. 
Lipid II and mutacin 1140 was used as a positive control for trapping lipid II at the 
origin. 
 
 
Figure184.7 Lipid II competition assay of nisin and mu1140-COOH analog. B. subtilis 
cells were treated with mu1140-COOH to compete with nisin in binding to lipid II A) 
Solvent blank (no antibiotic) control. B) Fluorescein labeled nisin binds tightly to lipid II 
to form patches. C) Prior treatment of cells with mu1140 prevents binding of fluorescein 
labeled nisin.  D) Prior treatment of cells with mu1140-COOH drastically reduces 
binding of fluorescein labeled nisin. Images were taken using a confocal Olympus 
microscope using a 100x objective, or a 40x objective for the control. 
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Table84.3 Competition MICs of mutacin 1140 or nisin against B. subtilis and M. luteus 
preincubated with mu1140-COOH. 
Antibiotic B. subtilis 
 MIC (ug/mL) 
B. subtilis comp. 
MIC (ug/mL) 
M. Luteus 
MIC(ug/mL) 
M. Luteus comp. 
MIC (ug/mL) 
Mutacin 
1140 
0.25 1.0 0.125 0.5 
Nisin 0.5 2.0 0.5 1.0 
     
IV.4. Discussion 
 The findings from this study show that decarboxylation in mutacin 1140 is not 
needed for the other PTM modifications. A fully modified analog of mutacin 1140 
without a C-terminal decarboxylation (mu1140-COOH) can be isolated and purified. 
The bactericidal activity of this analog can be restored by labeling the carboxyl group 
with a primary amine; a fluorescein conjugated mutacin 1140 can now be synthesized, 
enabling in vivo visualization of mutacin 1140 bound to lipid II target. Lastly, the loss of 
activity of the mu1140-COOH analog is likely due to the carboxyl group disrupting 
mutacin 1140 lipid II complex formation and not due to the complete loss of lipid II 
binding. These data support the need for a lateral assembly mechanism that traps lipid II 
into a complex for bactericidal activity, a mechanism that is distinct from other lipid II 
binding antibiotics, i.e. vancomycin (136). Furthermore, these data support future studies 
aimed at generating a C-terminal labeled library of mutacin 1140 analogs that may 
expand the antibiotic's application or therapeutic use. Our findings have opened a new 
avenue for the development of novel analogs for the epidermin group of lantibiotics. 
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  A variant of the epidermin group of lantibiotics with a C-terminal carboxyl group 
has never been isolated. A deletion of epiD showed no activity, but no discussion of an 
isolated product was mentioned (178). Presumambly, this is due to the lack of a product 
as was observed in the mutD deletion strain. Increasing activity or developing new uses 
for existing lantibiotics has been a goal of many researchers in the field. This has been 
achieved through a variety of methods, such as amino acid substitutions and the use of 
non-proteogenic amino acids (53, 98, 179). Semi-synthetic analogs of lantibiotics have 
been produced by chemically modifying lantibiotics (107, 108). The most common 
chemical modification of lantibiotics is through reactions with a free C-terminal 
carboxyl group. NVB302, is one such variant that has been chemically modified to have 
a diaminoheptane tail. This analog of actagardine has passed phase I clinical trials (113). 
Until the isolation of the mu1140-COOH analog, the presence of an AviCys residue on 
the epidermin group of lantibiotics prevented further development of novel analogs. The 
addition of a chlorinated aromatic ring may confer additional characteristics to mutacin 
1140, as is seen in vancomycin analogs in which the vancomycin analog inhibited 
transglycosylase activity (184). Additionally, we have been able to conjugate a 
diaminoheptane tail on mutacin 1140, similar to NVB302. All of these analogs were 
bioactive, however further characterization of these analogs are still needed to determine 
whether they improve the compounds activity or stability in animal studies.  
 Previously, visualization of the bioactivity by the epidermin group of lantibiotics 
was limited to in vitro assays due to limitations of not being able to conjugate a 
fluorescent probe to the antibiotic (52). The addition of a fluorescein label to mutacin 
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1140, for the first time, allowed for the in vivo visualization of this class of lantibiotic in 
action. These data have provided new insights into the importance of decarboxylation for 
bioactivity of the epidermin group of lantibiotics. Class 1 lantibiotics are known to bind 
to lipid II by forming a cage around the pyrophosphate residue using rings A and B (the 
lipid II binding domain) (154, 185). Furthermore, the latter half of the peptide is believed 
to help in the lateral assembly of the lantibiotic-lipid II complexes to form islands (51, 
186). In nisin, these islands form a pore complex, but the epidermin group primarily 
sequesters lipid II without forming a pore, as has been reported in fluorescently labeled 
lipid II vesicle experiments (50, 51). Decarboxylation was thought to be important, 
primarily, for stability of the peptide by preventing carboxypeptidases from degrading 
the lantibiotic (187). The loss of activity in the mu1140-COOH analog is intriguing and 
is likely to be the result of various factors, but our data suggests that the loss in activity 
is attributed, primarily, to loss in lateral assembly function. Microscopy studies show 
that mu1140-COOH can competitively bind to lipid II against nisin. Nisin and mutacin 
1140 have been shown not to interact with each other, indicating that the decrease in 
fluorescence by the fluorescein labeled nisin analog was due to competition with the 
lipid II target (52). Additionally, the mu1140-COOH analog was shown to have a 
protective function against wild-type mutacin 1140 and nisin. This suggests that the 
lateral assembly activity is crucial for bactericidal activity and the presence of the C-
terminal carboxyl group prevents mutacin 1140 forming a stable lipid II complex.  
 The influence of dehydrations and lanthionine ring formations on lantibiotic 
biosynthesis is well known (102, 163). Yet, little is known on how other PTMs influence 
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the biosynthesis of a functional lantibiotic. Studies have suggested that other PTM 
modifications, such as the N-terminal lactate of epilancin 15x, act independently of the 
dehydration and cyclase modifications found in lantibiotics(30, 87, 188, 189). Previous 
data has suggested that decarboxylation must occur before terminal ring formation due 
to a reactive ene-thiol intermediate that promotes terminal ring formation (177). 
Analysis of MrsD crystal structure has suggested that its active site cannot accommodate 
a lanthionine ring (176). Furthermore, attempts at decarboxylation of a lanthionine 
mimic proved futile (175). The lack of in vitro decarboxylation of mu1140-COOH 
shows that decarboxylation must occur before ring D formation suggesting that MutD 
cannot accommodate the terminal lanthionine ring into its active site. Additionally, the 
isolation of the fully modified mu1140-COOH analog demonstrates that terminal ring 
formation can occur regardless of the presence of a carboxyl group. 
During in vivo synthesis of mutacin 1140, mutations that prevent ring formation 
or dehydrations within the lantibiotic will have unpredicted affects on other PTMs 
within the peptide (32). A better understanding of the role of each PTM will promote the 
synthesis of novel analogs. We demonstrated that the bioactivity of the mu1140-COOH 
variant can be restored by capping the C-terminus with an amine (Table 4.1). The 
chemical synthesis of the AviCys residue is cumbersome (190, 191).  Our data 
demonstrates that chemical synthesis of this residue is not necessary for the epidermin 
group of lantibiotics and that solid phase peptide synthesis (SPPS) with differentially 
protected lanthionine can be used to synthesize this class of lantibiotics. Our study is a 
significant contribution to the field and provides new possibilities to synthesize novel 
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analogs of the epidermin group of lantibiotics. Moreover, our study has  provided new 
insight into the importance of decarboxylation for bioactivity.  
 
IV.5. Materials and methods 
IV.5.1 Bacterial strains and media 
 The bacterial strains and plasmids used in this study are outlined in table 4.4. S. 
mutans strains, B. subtilis PY79, S. pneumoniae, and M. luteus ATCC 10240 were 
grown in either THyex media agar (30g/L Todd Hewitt Broth, 3g/L yeast extract, 15g/L 
agar; Bacto, Sparks, MD), THyex broth ((30g/L Todd Hewitt Broth, 3g/L yeast extract), 
or THyex top agar (30g/L Todd Hewitt Broth, 3g/L yeast extract, 7.5g/L agar; Bacto, 
Sparks, MD). E. coli was grown in LB medium (10 g/L tryptone, 5 g/L yeast extract, and 
10 g/L NaCl, pH adjusted with NaOH to pH 7.5), Terrific Broth (12 g/L tryptone, 24 g/L 
yeast extract, 4 mL/L glycerol, and 2.2g/L KH2PO4 and 9.4g/LK2HPO4), or LB plates 
(10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl, 15g/L agar, and pH adjusted with 
NaOH to pH 7.5).   
 
Table94.4 Strains and plasmids used in chapter IV. 
Strain  Plasmid 
intermediate 
Relevant characteristic Reference or 
Source 
S. mutans JH1140 
(ATCC 55676) 
 WT bacteriocin producing 
strain 
Strain (124), 
ATCC 
S. mutans ΔmutA  mutA deletion strain (32) 
S. mutans IFDC2:mutD  mutD gene replacement with 
IFDC2 cassette 
This study 
S. mutans ΔmutD pΔmutD Clean deletion of mutD This study 
M. luteus ATCC 10240  Indicator strain for activity Strain  (40) 
B. subtilis PY79  Indicator strain for activity Strain (195) 
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IV.5.2 Gene deletion of MutD 
 Primers used for both sequencing and mutagenesis were designed using the S. 
mutans genome and lan cluster (GenBank/EMBL accession number AF051560). The 
IFDC2 gene replacement system was used, as previously described, to mutate or delete 
MutD(139). In-frame deletion cassette (IFDC2) is a gene replacement cassette 
containing a both a positive selection marker (ermAM) and a negative selection marker (-
pheS*). Approximately 500 bp upstream of mutD was amplified, and to prevent polar 
effects of downstream genes of mutD, a 500 bp fragment was amplified starting at 100 
bp upstream of the stop codon and 400 bp downstream of mutD. The fragments were 
attached to the 5’ and 3’ end of the IFDC2 cassette, respectively, by PCR. The final 3kb 
fragment was transformed into S. mutans ATCC 55676 by competent stimulating 
peptide (CSP) protocol (141). An overnight culture of S. mutans ATCC 55676 was 
diluted to 0.1 OD600 and incubated at 37 °C to 0.25 OD
600
. Two µl of 10µg/mL solution 
of CSP was then added to 200 µl of the 0.25 OD culture. After a 30 minute incubation 
time at 37 °C, 1µl of the PCR amplified product was added to the culture. The 
transformation was incubated at 37 °C for 5 hours before plating 50 µl of a 1000-fold 
Table 4.4 Continued    
Strain  Plasmid 
intermediate 
Relevant characteristic Reference or 
Source 
S. pneumoniae ATCC 
27336 
 Indicator strain for activity ATCC 
E. coli DH5α pCR2.1 and 
pET28B(+) 
Intermediate cloning host Invitrogen 
E. coli BL21  Protein overexpression host Invitrogen 
E. coli pmutD-kan pmutD-kan Codon optimized mutD This study 
E. coli pet28B:mutD pet28B:mutD MutD overexpression  This study 
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dilution onto a THyex plate containing 15µg/mL of erythromycin. Transformants were 
confirmed by PCR. The PCR products were inserted into a Topo PCR2.1® plasmid and 
were sent for sequencing. Both upstream and downstream regions were joined together 
and amplified to create the ΔmutD fragment. The ΔmutD fragment was transformed into 
S. mutans IFDC2:mutD, and selected on THyex plates (containing 4mg/mL of P-Chloro-
phenylalanine). 
Table104.5 Primers used in chapter IV. 
Primer Sequence (5’ to 3’) Characteristic 
MutD-
UpF 
GAT TTG TTT CGT AAA GAG GGT TC mutD gene 
replacement 
MutD-
DnR 
CTA CAT CAA TCC CAG AAT CAA C mutD gene 
replacement 
MutD-
UpR-IDH 
GAGTGTTATTGTTGCTCGGAAATTATTTCTCCGTTCAG TTAA mutD gene 
replacement 
MutD-
DnF-erm 
 
GGTATACTACTGACAGCTTCGGTAATTGTTGGACAAGAATC mutD gene 
replacement 
DelMutD-
F 
TTAACTGAACGGAGAAATAATTGGTAATTGTTGGACAAGAATC mutD clean 
deletion 
DelMutD-
R 
GATTCTTGTCCAACAATTACCAATTATTTCTCC GTTCAGTTAA mutD clean 
deletion 
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IV.5.3 Bioactivity assays 
 The deferred antagonism assay was performed as previously described 
(34). S. mutans strains were grown overnight in THyex broth at 37 °C.  The cultures 
were diluted to 0.1 OD OD600 and grown to mid-logarithmic phase before diluting to 
0.05 OD600. Then, 2µl of the cultures were spotted on THyex plates in duplicates of 
triplicates. The wild-type S. mutans JH1140 and S. mutans ΔmutA were used as positive 
and negative controls for activity, respectively. The plates were incubated for 18 hours in 
a candle jar at 37 °C. After incubation, the strains were heat killed at 65 °C for 90 
minutes. Fresh M. luteus grown overnight at 37 °C on THyex plates were used to 
inoculate pre-warmed THyex broth. The culture was grown to 0.6 to 0.8 OD before 
diluting to 0.2 OD600. The culture was further diluted 25-fold in melted (42 °C) THyex 
top agar. Approximately 5mL of the top agar solution was spread on the heat killed 
bioassay plates and allowed to cool for 10 minutes. The plates were the place in the 
incubator (at 37 °C) for 18 hours.  
 The MICs were determined according to previously published protocol (40). A 
stock solution of the antibiotics tested was first suspended in 50% acetonitrile (ACN) at 
a concentration 640 µg/mL. This stock was subsequently diluted 2-fold until a final 
concentration 0.156 µg/mL was reached. Subsequently, 10ul of each dilution was placed 
into a well on a 96 well microtiter plate. M. luteus ATCC 10240, S. pneumoniae, and B. 
subtilis PY79 were grown overnight in THyex at 37 °C. Cultures were diluted in the 
morning to 0.1 OD600 and allowed to grow to 0.6 OD600. This culture was diluted a 100-
fold in fresh THyex media and then 400ul of this culture was added to 10mL of fresh 
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THyex. The suspension contains approximately 10
5
 colony forming units (CFUs). The 
bacterial suspension (190 µL) was added to each well containing 10 µL of antibiotic 
suspension or solvent blank. This results in another 20-fold dilutions of the antibiotic 
suspension. For the competition assays, the 10
5
 CFU bacterial suspension was initially 
mixed with mu1140-COOH for 15 minutes at the 1X MIC of either mutacin 1140 (0.25 
µg/mL and 0.125 µg/mL for B. subtilis and M. luteus, respectively) or nisin (0.5 µg/mL 
for B. subtilis and M. luteus). Following the 15 minute pretreatment, 190 µL was added 
to each well as described above. The MIC is described as the lowest concentration of 
antibiotic that prevented visible growth after 24 hours. 
  
IV.5.4 Production and purification of mutacin 1140 and mu1140-COOH 
 Lanthipeptides isolated in this study were cultures as stated previously(192). S. 
mutans strains were grown in a modified THyex media. The media contained 30g/L 
Todd Hewitt, 3g/L yeast extract,  1 g/L NaH2PO4, 0.2 g/L Na2HPO4, 0.7 g/L MgSO4, 
0.005 g/L FeSO4, 0.005 g/L MnSO4, and 0.3% agar. The semi-solid agar (1 L) was 
inoculated with various strains of S. mutans and incubated at 37 °C for 72 hours. After 
incubation, the inoculum was frozen at -80 °C overnight and thawed for 1 hour in a 65 
°C water bath. The inoculum was then centrifuged at 20,000 G for 30 minutes and the 
supernatant was collected. The supernatant was mixed with chloroform at a 1:1 ratio and 
shaken vigorously. This mixture was again centrifuged at 20,000 G for 30 minutes. The 
precipitate between both the aqueous and chloroform phases was collected and dried 
overnight. The dried product was resuspended in 35% ACN containing 0.1% 
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trifluoroacetic acid (TFA) and ran on either a semi-prep C18 column (Agilent® 
ZORBAX, ODS, C18, 5µm, 4.6x250mm) or analytical column. Peaks collected were 
confirmed by mass on a Shimadzu® MALDI-MS on both linear and reflectron modes. 
 
IV.5.5 Chemical modification of mu1140-COOH and nisin 
Labeling of C-terminal carboxyl group with methylamine (33% in EtOH) 
(Sigma-Aldrich), diaminoheptane (Sigma-Aldrich), 4-chlorobenzylamine (Sigma-
Aldrich), 3,4-dichlorobenzylamine (Sigma-Aldrich), or 5-(aminoacetamido)fluorescein 
(Sigma-Aldrich) was done by 1-Hydroxy-7-azabenzotriazole/1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (HOAt/EDC) coupling. The labeling was done in 
accordance to a previously described method(34, 51). The reaction mixture was 
suspended in 100 µl of dimethyl formamide (DMF) with 50 nmols of either nisin, or 
mu1140-COOH, 50 nmols AAA-fluorescein or 200 nmols of the primary amine, 60 
nmols of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and 60 nmols of 1-
hydroxy-7-azabenzotriazole (HOAt). The reaction was covered in foil and incubated at 
room temperature for approximately 16 hours. The reaction was subsequently diluted 
10-fold with 35% ACN containing 0.1% TFA and ran on an analytical C-18 column. 
The labeled peptides were confirmed by MALDI-MS as described above. The amount of 
chemically conjugated product was determined by Bradford Assay using manufacturer 
protocols (Sigma-Aldrich). The purified labeled peptides were then dried down and 
resuspended in 35% ACN containing 0.1% TFA at a concentration of 100ug/mL and 
stored at -20 °C.  
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IV.5.6 Microscopy 
 B. subtilis PY79 was grown and treated with fluorescein labeled peptide as 
previously described (34). A fresh plate of B. subtilis was used to inoculate THyex broth 
and incubated approximately 16 hours at 37 °C. The culture was diluted 20-fold and 
place back in the incubator for 3 hours at 37 °C.  Then, 100 µl of the culture was 
incubated with the antibiotic (10µg/mL) for 15 minutes. The cells were pelleted and 
resuspended in 100 µl of phosphate buffer solution (PBS). The wash step was repeated 
three times before fixing with 1.6% formaldehyde in PBS. After fixation the cells were 
washed with PBS three more times and the remaining pellet was suspended in 50 µL of 
PBS. The sample (30 µL) was added to a slide and observed using an Olympus confocal 
microscope with a 100×/0.90 dry objective. A 488 nm argon laser was used to excite the 
fluorophore. For the competition assay, the bacterial culture was initially incubated with 
mu1140-COOH or native mutacin 1140 at a concentration of 10 µg/mL for 15 minutes, 
washed, and resuspended in fresh media. 10 µg/mL of fluorescein labeled nisin was then 
added for 15 minutes, before following the wash protocol previously stated.  
 
IV.5.7 Mu1140 double labeling and Edman sequencing 
 Edman sequencing has been frequently used to determine the sequence of small 
peptides, such as lantibiotics (193, 194). Mu1140-COOH was doubly labeled as 
previously described for mutacin 1140 (29). A 200 µM solution of Mu1140-COOH in 
5µl of water was added to a reaction tube containing 2 mg of sodium borohydride.  
Then, 94µL of solution B (570 mg guanidine HCl, 100 mL N-ethylmorpholine and water 
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to a final volume of 1 mL; the pH of the mixture was adjusted to 8.5 with glacial acetic 
acid) was added to the reaction mixture and placed into a glass vial. The reaction vial 
was purged with nitrogen and stored at 37 °C for three days. The peptide was then 
loaded onto a prosorb column (Applied Biosystems) and absorbed onto a PVDF 
membrane. After drying the PVDF membrane, 15 ul of solution A (280 µL methanol, 
200 µL water, 65 µL 5 M sodium hydroxide, 60 µL ethanethiol) was added to the 
membrane. The reaction was sealed tightly and incubated at 50 °C for 1 hour. After the 
reaction, the sample was sent out for Edman sequencing. The glass fiber filter used in the 
Edman sequencing was pretreated with polybrene to reduce the loss of peptide per cycle. 
After drying in nitrogen, the PVDF membrane was excised and loaded onto a sequencer 
(Applied Biosystems 492 Protein P.E. Biosystems, Foster City, CA, USA). The 
sequence was analyzed by the ABI 610A data software. D,L-2-aminobutyric acid was 
commercially purchased from Sigma Aldrich and used as a standard. 
 
IV.5.8 MutD cloning and purification 
 A codon optimized sequence of mutD for E. coli was purchased from Integrated 
DNA Technologies (IDT, Coralville, IA). According to manufacturer’s specifications, 
the mutD gene was cloned into the Xho1 site within the pET28B(+) expression vector 
(EMD Millipore, Billerica MA) providing an N-terminal His-tag. The ligation was 
transformed into E. coli DH5α and confirmed by sequencing. The plasmid was then 
transformed into the E. coli BL21 expression strain. A fresh plate of E. coli BL21 
pET28B(+):mutD was restreaked onto LB plate containing 50 µg/mL kanamycin (kan) 
 115 
 
prior to induction. One colony from the plate was suspended in 1 L of Terrific broth 
containing 50 µg/mL kan. Before the addition of IPTG (250ul of a 1M solution), the 
culture was shaken at 37 °C until an OD600 of 0.8 was reached. Following induction, the 
culture was incubated with shaking at 18 °C for approximately 16 hours. The culture was 
then spun at 4000 x g for 30 minutes at 4 °C. The pellets were resuspended in 25mL of 
lysis buffer (500mM NaCl, 50mM Tris-HCl, 15 mM imidazole, 1mM PMSF, 10% 
glycerol, at pH 7.5), before adding 500µl of the lysozyme solution (50mg/mL). The 
solution was mixed and stored on ice for 30min. The suspension was lysed using a 
sonicator at medium setting for 10 minutes with 1 minute intervals, taking care to not 
overheat the solution. The lysate was then centrifuged at 16,000 x g, and the supernatant 
was collected. 500 µl of Ni-NTA beads were added to the supernatant and placed on a 
shaker for approximately 16 hours at 4 °C. The Ni-NTA beads were collected by 
centrifugation at 3,000 RPM for 10 minutes at 4 °C. The beads were washed three times 
with 10x bead volume of lysis wash buffer (500 mM NaCl, 50 mM Tris-HCl, 30 mM 
imidazole, 1mM PMSF, at pH 7.5). After washing, the beads were eluted by 
resuspending in 500 µL of lysis buffer containing 0.5 M Imidazole. The suspension was 
place on a shaker for 1 hour at 4 °C and the elution was repeated three times. The 
elutions were run on an SDS Page gel to determine purity of the MutD. The 
deacarboxylase was further run on an FPLC. Protein concentrations were determined by 
Bradford assay (Sigma-Aldrich).  
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IV.5.9 In vitro decarboxylation 
 In vivo decarboxylation was performed as previously described by Kupke et al 
(175). A control substrate, SFNSYTC was purchased from Peptide&Elephants. A 1 
mg/mL solution of either SFNSYTC or mu1140-COOH in Tris-HCl buffer (pH 8.0) 
containing 3mM DTT was prepared. The peptide solution (100 µL) was incubated with 
MutD (30 µg/mL) for 1 to 10 hours at 37 °C. The sample was diluted 10-fold in 35% 
ACN containing 0.1% TFA before being loaded on the RP-HPLC as previously 
described(40). The masses of the isolated fractions were determined by MALDI-MS. 
 
IV.5.10 Lipid II binding assay 
 Lipid II was a kind gift from Eefjan Breukink and was resuspended in a 1:1 
Methanol:Chloroform solution. The lipid II binding assay using thin layer 
chromatography (TLC) was done as previously described (34). The mobile solvent 
consisted of consisted of butanol:acetic acid:water:pyridine (15:3:12:10 
[vol/vol/vol/vol]). A 0.2 mM solution of mutacin 1140 or mu1140-COOH in 10 µL of 
solution A was mixed with lipid II (final 6.8 mM) for 1 hour in a sealed glass vial. This 
corresponded to a ratio 3:10 peptide:lipid II ratio. All of the reaction mixtures and the 
appropriate controls were spotted (5 µL) 2 cm from the bottom of the plate. These spots 
define the origin of the plate. Lipid II and peptide alone were used as a control to 
demonstrate that the origins do not stain unless peptide and lipid II are added together. 
The mobile phase was allowed to climb up the plate until it reached a centimeter from 
the top. The plate was allowed to dry before staining with iodine. 
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CHAPTER VI:                                                                                                 
CONCLUSION 
 Ever since the discovery of penicillin, the threat of antibiotic resistance has been 
a concern for public health officials and scientists across the world. In modern times, this 
threat has become an ever-concerning reality. Public health has become increasingly 
threatened by multi-drug resistant bacteria. The term “superbug” is increasingly heard in 
news articles, which have conveyed a sense of an upcoming antibiotic apocalypse (1). 
Yet, the real cost of these pathogenic bacteria is hard to ignore. MRSA has become one 
of the leading causes of hospital deaths across the world (118). Furthermore, the 
naturally antibiotic resistant spore-forming bacteria, C. difficile, has become one of the 
most persistent hospital acquired infections (118). Even vancomycin, which is known as 
a drug of last resort, is becoming increasingly susceptible to antibiotic resistant 
organisms (125). Healthcare systems have seen an increase in healthcare spending due to 
these infections (2, 3). These pathogens have put an immense burden on healthcare 
systems in the world. As such, the CDC and other public health agencies have identified 
ways to combat this problem. The development of novel types of antibiotics has become 
one of the key tools in combating this problem. Bacteriocins, like mutacin 1140 and 
other lantibiotics, may assist in alleviating the burden on healthcare. 
 Lantibiotics have become an enticing candidate for development due to their 
unique structure, target, and lack of antibiotic resistance (9, 17). Development of 
mutacin 1140 and other lantibiotics requires an understanding of the mechanism of 
biosynthesis. The key components of lantibiotic biosynthesis are known and much 
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research has been done on them. Dehydrated serines and threonines are important, 
especially ones that are involved in lanthionine ring formations. The thioether linkages 
found in lanthionine rings are absolutely important for activity and stability of the 
bacteriocin (32, 34, 163). The PTM enzymes themselves have also been studied 
extensively. Crystal structures and mechanism of actions for the dehydratase, NisB, and 
the cyclase, NisC have been elucidated (102, 103). Furthermore, LanM, found in class II 
lantibiotics, has been shown to have enough freedom to modify other peptides (43, 44). 
LanP, is similar to other serine proteases. While the transporter, LanT, is similar to other 
ABC-type transporters. The immunity genes found in lantibiotics are composed of a 2-
component histidine kinase system. Even though lantibiotics may share similar core 
peptide structures and PTM enzymes, the coordination or PTM modifications, transport 
and regulation are divergent. 
 Mutacin 1140, as a member of the epidermin class of lantibiotics has several 
shared structural elements found within the core peptide (171). It has a similar lipid II 
binding domain to epidermin and nisin, but its lateral assembly domain is distinct from 
nisin (171). The C-terminus of the lateral assembly domain of the epidermin class is 
capped to form a C-terminal AviCys residue. The mutacin 1140 leader peptide is 
structurally unique compared to the epidermin class of lantibiotics. As a therapeutic, 
mutacin 1140 has shown tremendous promise. It has been shown to be active against 
various Gram-positive pathogens in in vitro assays. It has been shown to clear infections 
in murine models (14). Yet it is plagued with the same problems that other lantibiotics 
have faced, which is the low fermentation yields found in this type of bacteriocins and 
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the short half-life in animals (14, 36). That is why it is imperative to study the 
biosynthesis of lantibiotics, such as mutacin 1140, to help in its development. 
 Our studies have shown that the unique structure of the mutacin 1140 leader 
peptide is important for biosynthesis. Mutacin 1140 has a 61 amino acid leader peptide, 
which is longer than other lantibiotic leader peptides with a similar core peptide 
structure. Deletions of the N-terminal part of the leader peptide have suggested that 
length not the secondary structure is important for N-terminal portion of the leader 
peptide. This lack of sequence specificity in portions of the leader peptide is similar to 
the nisin leader peptide (127). The lack of specificity is in contrast with the class II 
lantibiotic, lacticin 481, which shows that proline insertions do affect the production of 
the lantibiotic (123). Protein structure predictions of mutacin 1140 suggest that there 
may be a certain preference of amino acid sequence in the leader peptide which do not 
sterically hinder binding to the target (24). The presence of a specific four amino acid 
motif has been shown to be important in the biosynthesis of most lantibiotics. The EDLF 
motif in mutacin 1140 is unique compared to other class I lantibiotics which contain the 
FNLD box (123, 128). Products obtained from mutants in the EDLF box suggest that the 
leader peptide binds to a single site on one of the PTM enzymes. Binding studies on the 
nisin leader peptide suggest the FNLD box is important for binding to the dehydratase, 
NisB (127). Our model suggest that the length of the leader peptide is important for 
initial binding and stabilizing interactions with presumably the MutB dehydratase, while 
the EDLF motif is essential for anchoring the leader peptide to a defined site within the 
dehydratase. Having a defined binding site within the leader peptide and the dehydratase 
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is important for coordinating the PTM modifications on the core peptide ensuring that 
the PTM modifications are occurring in the correct order enabling the synthesis and 
transport of a functional bacteriocin.   
 Proteolytic cleavage of the leader peptide is an important step in the production 
of lantibiotics. It has always been assumed that a single proteolytic cleavage is required 
for lantibiotics. The specificity of the protease in removing the leader peptide is not well 
understood. Some models suggest that the transporter may help guide the core peptide to 
the protease. Yet deletion of the transporter, MutT, did not change the activity or mass of 
the product isolated. Mutations in the nisin core peptide suggest that the core peptide 
itself governs cleavage at the normal site (117, 153, 165). Our data suggest that this may 
also be the case, wherein the removal of rings A and B, by alanine substitution at 
cysteine positions seven and eleven, had a product with eight amino acids of the leader 
peptide attached. Furthermore, a single ring A mutant produced a mutant with a cleavage 
site found internally of the core peptide. The presence of an 8 amino acid leader peptide 
to mutacin 1140 in a ΔMutP mutant suggests that another proteolytic cleavage occurs. 
Studies by Rink et al have shown that partial cleavage of the leader peptide does occur 
in strains without NisP, yet the major product includes the whole leader peptide (162). In 
contrast, the deletion of MutP clearly shows a single partially cleave product, suggesting 
a different sort of mechanism for partial cleavage. The secondary cleavage site is 
position specific, with the cleavage occurring at various regions of the leader or core 
peptide depending on the mutations made at the C-terminal end of the leader peptide. A 
deletion of the amino acids (-7 to -2) positions shifted the cleavage site into the core 
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peptide. This observation suggests coordination between the different PTM enzymes. 
Our model proposes that MutB and MutC activity is coordinated by structural dynamics 
of the modified core peptide, wherein full modification would trigger interaction with 
the transporter and release of the core peptide from MutB by the secondary cleavage site 
at the -8 position. Our model suggests that the last PTM modification would be the 
formation of ring D, which is essential for the transport of the core peptide. 
 One model of lantibiotic biosynthesis suggests that cyclization and dehydration 
occur independently of each other (126). Another models of biosynthesis challenges this 
model and suggest that PTM dehydration and cyclization modifications occur 
concurrently by binding of the leader peptide to a single enzyme (127). Our data on the 
dehydration and cyclization of the lanthione rings advocates the latter model of 
biosynthesis. Mutations on some of the rings resulted in the lack of dehydrations on 
some of the serines and threonines at other positions within the core peptide, which 
suggests coordination between these two PTM modifications. Interestingly, one minor 
product also included a variant that had a carboxyl group on the C-terminus, which has 
never been isolated in this class of lantibiotics. The mechanism for knowing how PTM 
system recognizes a fully modified peptide for transport has not been elucidated. The 
lack of any product from a ring D mutant suggests that ring D formation, which is 
assumed to be the last PTM modification, is the deciding factor for transport outside the 
cell. Preventing the formation of both rings C and D still yielded significant levels of 
transported product. This further gives credence to the PTM coordination model of 
lantibiotic biosynthesis where the leader peptide provides an anchor for the core peptide 
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modifications, in lieu of the movement of the leader peptide between PTM enzymes for 
subsequent modifications (123). 
 Although lantibiotic biosynthesis models and studies have mainly focused on the 
primary forms of modification, understanding other types of PTM modifications is still 
important. Lantibiotics contain numerous post-translational modifications, each with 
varying degrees of importance to the activity and biosynthesis of the bacteriocin. The 
importance of the AviCys residue in mutacin 1140 and other epidermin class lantibiotics 
is unknown. The crystal structure of the decarboxylase and the proposed mechanism of 
formation of the AviCys have been elucidated, but their role in bioactivity has not been 
elucidated until our study (137, 176). Cross species production of EpiA have suggested 
that decarboxylation is important for preventing proteolytic degradation of the 
bacteriocin (187). The isolation of a carboxyl variant of mutacin 1140 is the first 
instance of an epidermin class of lantibiotic with a carboxyl group at the C-terminus. 
Furthermore, this variant contains all the modifications except for the decarboxylation, 
demonstrating that decarboxylation is not important for the full biosynthesis of the 
peptide. The study also supports the notion that decarboxylation would have to occur 
before ring D formation, which we suggest is important for transport. The lack of 
activity of this analog shows that decarboxylation is crucial for activity. The presence of 
a negative charge at the C-terminus in physiological conditions may affect lateral 
assembly of the lantibiotic-lipid II complex. Binding data to lipid II shows that the 
mutacin–COOH can still bind to lipid II, which shows that presence of a carboxyl group 
prevents lateral assembly of the complex. This observation has been found in nisin, 
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wherein an intact lipid II domain did not have activity. Interestingly, similar to nisin AB 
fragment, mu1140–COOH bound to lipid II at a lower affinity. Previous studies have 
suggested that the lateral assembly domain is important for stabilizing the binding to 
lipid II. My research shows decarboxylation may not be important for full biosynthesis, 
but it is absolutely necessary for the antibacterial activity of mutacin 1140. 
 The presence of the AviCys residue has always posed a challenge for the 
development of the epidermin class of lantibiotics. This has hampered chemical 
synthesis of the epidermin class of lantibiotics by adding a cumbersome step for 
synthetic synthesis (190. 191). Due to low yields of lantibiotics by naturally producing 
organisms, solid-phase synthesis of lantibiotics has become an attractive option for 
production. Unfortunately, the AviCys residue prevents chemical modification of this 
class to produce novel C-terminal analogs. C-terminal modification of lantibiotics, such 
as nisin, has produced novel analogs that have additional characteristics (105-107). Our 
production of novel analogs of mutacin 1140 by chemically modifying the C-terminus of 
mu1140-COOH solves this problem. Furthermore, restoration of activity shows that 
producing the AviCys residue is not needed, but simply capping the C-terminus restores 
activity. A variant of deoxyactagardine B, NVB302, with a diaminoheptane tail has gone 
through phase I clinical trials (113). The addition of a diaminoheptane tail on the end of 
mutacin 1140 restores activity, yet further studies are needed to evaluate how this analog 
may affect its application for treating a bacterial infection. The formation of a carboxyl 
variant or mutacin 1140 will promote new drug development studies and further the 
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potential for chemically synthesizing active analogs of the epidermin class of 
lantibiotics. 
 The competing models of lantibiotic biosynthesis has shown that further studies 
are needed to fully understand PTMs of lantibiotics. Our studies have shown that 
lantibiotic biosynthesis follows the coordinated PTM model. Wherein, the leader peptide 
acts as an anchor on MutB while the dehydratase and cyclase modify the peptide in a 
coordinated manner. Decarboxylation of MutD is assumed to occur before ring D 
formation. Finally formation of ring D signals the peptide to be transported out of the 
cell, and subsequent leader peptide cleavage produces the active peptide antibiotic. 
Although there is a clearer picture in mutacin 1140 biosynthesis, there are still many 
challenges ahead in producing mutacin 1140 as a therapeutic. The low yields by 
lantibiotics still pose a problem in scaling up production. Yet our recent data has shown 
that by manipulating the mutacin 1140 regulatory pathway, the production of the 
lantibiotic can be increased. Furthermore, mutacin 1140 has a short half-life in vivo (ref), 
the synthesis of new variants of mutacin 1140 by chemically modifying the peptide 
could solve this problem. Due to its broad spectrum of activity against Gram-positive 
bacteria and the lack of resistance of pathogenic bacteria to mutacin 1140, supports the 
need for additional studies aimed at furthering its use to treat infections. The mutacin-
COOH variant is a great scaffold for producing novel analogs by coupling the C-
terminus. Mutacin 1140 and other lantibiotics have shown promise inthe fight against 
antibiotic resistance. Research into these class of bacteriocins has grown over the years, 
yet much needs to be done.  
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